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ABBREVIATIONS 
 
 
Amino Acids: singol and 3 letters code 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BSE            Bovine Spongiform Encephalopathy 
Boc             Tert-butoxycarbonyl 
BOP            Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium     
                   hexafluorophosphate 
CD              Circular Dichroism 
CJD            Creutzfeldt-Jakob Disease  
DCM           Dichloromethane 
DIEA           N,N-diisopropylethylamine 
DMF            Dimethylformamide 
DRM           Detergent Resistant Microdomains  
ER              Endoplasmic Reticulum 
FC               Fatal Concentration 
GPI             Glycosyl Phosphatidyl Inositol 
GSS           Gerstmann-Straussler-Scheinker 
HBTU         2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium       
                   hexafluorophosphate 
HCl             Chlorhydric acid 
hPrP           human Prion Protein 
LC               Liquid Chromatography  
MTT            3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide      
NaOH         Sodium hydroxide 
PrP             Prion Protein 
PrPC            Cellular form of Prion Protein 
PrPSc               Scrapie form of Prion Protein 
MD              Molecular Modelling 
MeOH         Methanol 
mPrP          murin Prion Protein 
MS              Mass Spectroscopy  
nd               not detected 
NMR           Nuclear Magnetic Resonance 
Pbf              2,2,4,6,7-Pentamethyldihydro-benzofuran-5-sulfonyl 
SDS           Sodium dodecyl sulfate 
A   Ala 
βA  β-Ala          
N   Asn           
R   Arg            
D   Asp           
C   Cys           
Q   Gln            
G   Gly            
E   Glu            
H   His             
I     Ile              
Alanine  
β-Alanine 
Asparagine 
Arginine 
Aspartic Acid 
Cysteine 
Glutamine 
Glycine 
Glutamic Acid 
Histidine 
Isoleucine 
L  Leu           
K  Lys            
M  Met             
F   Phe            
P   Pro       
S   Ser            
T   Thr            
W  Trp             
Y   Tyr             
V   Val              
Leucine  
Lysine 
Methionine 
Phenylalanine 
Proline 
Serine 
Threonine 
Tryptophan 
Tyrosine 
Valine 
  
2 
SPPS         Solid Phase Peptide Synthesis 
sPrP           sheep Prion Protein 
tBu             Tert-Butyl 
TC              Tetracycline  
TFA            Trifluoroacetic acid 
TFE            Trifluoroethanol 
TIS             Tri-isopropyl-silane 
Trt              Trityl 
TSE           Transmissible Spongiform Encephalopathies 
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SUMMARY 
 
 
A large number of human disorders, ranging from type II diabetes to Parkinson’s and 
Alzheimer’s diseases, are associated with protein aggregation resulting from aberrant 
folding or processing events. Despite its fundamental biological importance, little is 
known about the molecular basis or specificity of the general phenomenon of protein 
aggregation. Transmissible spongiform encephalopathies, also known as prion 
diseases, belong to this class. They are all characterized by progressive neuronal 
degeneration. In almost all cases there is a marked extracellular accumulation of an 
amyloidogenic conformer of the normal cellular prion protein (PrPC), referred to as 
the scrapie isoform (PrPSc), which is thought to be responsible for the disease 
symptoms.  
PrP is an ubiquitous 231-amino acid glycoprotein whose physiological role is still 
elusive. Its structure exhibits an N-terminal unfolded region and a C-terminal globular 
domain characterized by the presence of three α-helices (α1, α2 and α3), two short 
β-strands and an interhelical disulfide bridge between the α2 Cys179 and the α3 
Cys214, which confers structural stability. Particularly fascinating is the notion that 
the protein possesses one or several ‘spots’ of intrinsic conformational weakness, 
which may lead the whole secondary and tertiary structure to succumb in favour of 
more stable, but aggregation-prone conformations, depending on pH, redox condition 
or glycosylation. The C-terminal side of helix 2, containing four adjacent threonines, 
is decidedly suspected to be one of such spots and, in this regard, has recently 
gained the attention of several investigations. As the α-helix 2 possesses chameleon 
conformational behaviour, gathers several disease-associated point mutations, can 
be toxic to neuronal cells and strongly fibrillogenic, it is a suitable model to 
investigate both structural determinants of PrPC misfolding and rational structure-
based drug design of compounds able to block or prevent prion diseases. The 
intriguing structural properties of this protein domain prompted us to investigate the 
conformational landscape of the α-helix 2 domain.  The α-helix 2 of hPrP was used 
as a template for designing α2-helix-derived peptides, which were synthesized by 
SPPS and characterized by CD and NMR in aqueous buffer at different pH, in 
structuring media (SDS and TFE) and in presence of anions and bivalent metal 
cations. Finally, the neurotoxicity of these peptides was also assayed on B104 
neuroblastoma cells. Overall, these studies strongly suggest that the role played by 
the α-helix 2 domain is not to be considered neutral in the misfolding mechanism of 
the PrPC to the scrapie isoform. In addition, the affinity of the α-helix 2-derived 
peptides for potential PrP-binding molecules was investigated by integrated 
spectroscopical (CD and steady-state fluorimetry) and computational studies 
(molecular dynamic simulations and docking calculations).  
In particular, we have shown that the antibiotic tetracycline can strongly interact with 
the α-helix 2  and that interaction concerns residues within its C-terminal half, 
previously suggested as a good candidate to promote a local α→β transition.  
Finally, preliminary results on the interaction between the α-helix 2 and peptide 
constructs, designed on a Fab-ovPrP crystallographic complex, could open 
interesting perspectives for the diagnostic or therapeutic use of these molecules in 
PrP-associated diseases and give useful hints on the region/residues potentially 
important for the PrPC→PrPSc conversion and on the conformational rearrangements 
involved in prion misfolding.  
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RIASSUNTO 
 
 
Un numero crescente di malattie neurodegenerative quali i morbi di Alzheimer, di 
Parkinson e di Huntington, il diabete di tipo II e la fibrosi cistica, sono attualmente 
identificati come “malattie conformazionali”, nelle quali le normali funzioni cellulari 
risultano compromesse da misfolding e aggregazione proteica [1]. Il folding anomalo 
della proteina prionica (PrPC), in particolare, costituisce l’evento chiave alla base di 
patologie note come “encefalopatie spongiformi trasmissibili” (TSE) [2]. 
Il riarrangiamento strutturale di PrPC nella forma patologica scrapie (PrPSc) e la 
conseguente formazione di fibrille amiloidi accomuna le TSE alle altre malattie 
conformazionali [3]. Pertanto, lo studio delle preferenze conformazionali della PrP 
potrebbe fornire un valido modello per la comprensione dei meccanismi del 
misfolding proteico.  
La PrP è una glicoproteina di 231 amminoacidi presente nel sistema nervoso e 
linfatico, il cui ruolo fisiologico rimane ancora da chiarire, sebbene numerose ipotesi 
siano state avanzate riguardo a un suo coinvolgimento nel trasporto del rame e dello 
zinco, nell’apoptosi, e nella protezione da stress ossidativi [4]. Essa è caratterizzata 
da una zona N-terminale disordinata e flessibile e da un dominio C-terminale 
costituito da 3 α eliche (α1, α2 e α3), 2 β-strands ed un ponte disolfurico fra Cys179 
e Cys214, che collega l’elica α2 con l’elica α3 conferendo stabilità strutturale all’intero 
dominio [5]. Particolarmente suggestiva è l’ipotesi che la proteina possegga uno o 
più siti di intrinseca fragilità strutturale che potrebbero costituire il punto di partenza 
della transizione PrPC→PrPSc e, quindi, di nucleazione per la formazione di strutture 
β-sheet. A tale proposito, di particolare interesse risulta lo studio del frammento C-
terminale dell’elica α2 che, per la presenza di 4 treonine consecutive nella sua 
sequenza [6], potrebbe costituire uno dei tratti di PrP caratterizzati da una 
propensione ad assumere una conformazione di tipo β.   
In particolare, lo studio dell’elica α2, la cui sequenza peptidica è caratterizzata da 
ambivalenza conformazionale [7], dalla presenza di mutazioni amminoacidiche 
associate a patologie [8] e da neurotossicità [9], risulta particolarmente utile non solo 
per indagare i determinanti strutturali del misfolding prionico ma anche per il de novo 
design di composti in grado di prevenire o bloccare le malattie da prione. 
A partire dalle particolari caratteristiche strutturali di questo sotto-dominio proteico, 
nel corso del lavoro di tesi, sono state analizzate le proprietà conformazionali della 
sequenza peptidica 173-195 corrispondente all’elica α2 della proteina prionica 
umana ed è stata inoltre valutata la sua affinità nei confronti di molecole 
peptidomimetiche ed organiche con potenziale attività anti-prionica.  
A tale scopo, sono state sintetizzati, mediante metodiche in fase solida, i peptidi 
riportati in Tabella 1(A), nella forma N- e C-terminale protetta, e quelli riportati in 
Tabella 1(B), funzionalizzati mediante fluoresceina. In particolare, i peptidi PrP[173-
195] e PrP[173-195]D178N, corrispondenti all’intera sequenza dell’elica α2 della 
proteina prionica umana, rappresentano, rispettivamente, il wild type ed il suo 
analogo D178N recante la mutazione amminoacidica associata alla sindrome di 
Creutzfeldt-Jakob (CJD) [10]. Il peptide PrP[180-195] costituisce il frammento più 
corto dell’elica α2, comprendente la sua zona C-terminale, ricca di treonine e 
caratterizzata da una forte propensione a formare strutture di tipo β, ed il peptide 
PrP[173-179] è il suo segmento complementare. 
Il peptide  PrP[180-195]H187A è stato infine scelto allo scopo di analizzare il ruolo 
del residuo di His187 nell’arrangiamento strutturale del frammento 180-195. 
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Tabella 1 Abbreviazione e sequenza dei peptidi sintetizzati. 
 
 
Nel corso del lavoro sperimentale, sono stati quindi condotti: 
 
1) Studi comparativi mediante CD, NMR e test di tossicità cellulare sul peptide 
PrP[173-195], sull’analogo PrP[173-195]D178N e sui frammenti PrP[180-195] e 
PrP[173-179], allo scopo di chiarire il ruolo strutturale che l’intero dominio dell’elica 
α2, ed in particolare la sua parte C-terminale, riveste nel misfolding della proteina 
prionica ed inoltre l’influenza che mutazioni amminoacidiche legate alle TSE possono 
avere sulla sua stabilità e tossicità.  
Dall’analisi mediante CD emerge che i peptidi PrP[173-195], PrP[173-195]D178N e 
PrP[173-179] assumono in acqua una conformazione di tipo random. Al contrario, il 
frammento PrP[180-195] mostra nelle stesse condizioni una conformazione di tipo β, 
che rimane sostanzialmente invariata in presenza dell’agente α-strutturante TFE. È 
quindi ragionevole ricondurre la conformazione random dell’intero frammento 173-
195 al suo segmento N-terminale che è probabilmente in grado di attenuare la forte 
propensione β della parte C-terminale.  
Inoltre, la sostituzione del residuo di Asp178 carico negativamente  con uno neutro di 
Asn che è associata alla sindrome CJD, conferisce al peptide PrP[173-195]D178N 
una maggiore propensione ad assumere una conformazione di tipo β in SDS rispetto 
al peptide wild type nelle stesse condizioni.  
L’analisi mediante NMR dimostra che la conformazione α-elicoidale, mostrata dal 
peptide wild type in TFE, riarrangia nel peptide mutato in due piccole α eliche 
separate da un ripiegamento centrato sulla Lys185 e la Gln186.  
Test di tossicità condotti su cellule B104 di neuroblastoma di ratto hanno infine 
dimostrato che il peptide PrP[173-195]D178N esibisce una tossicità più alta (FC50=12 
µM) rispetto al peptide wild type (FC50=68 µM), probabilmente a causa della 
destabilizzazione strutturale legata alla sostituzione Asp178 con Asn. 
 
2) Analisi mediante CD sull’influenza del pH e della forza ionica sulla conformazione 
del peptide PrP[180-195] ed del suo analogo PrP[180-195]H187A. 
Abbiamo dimostrato che anioni caotropici, quali Cl−, ClO4−, e H2PO4−, debolmente 
idratati a causa della loro bassa densità di carica, favoriscono l’accessibilità del 
solvente alla superficie peptidica e, quindi, una conformazione scarsamente 
strutturata dei peptidi, mentre anioni cosmotropici, quali SO42− e HPO42−, fortemente 
idratati grazie alla loro alta densità di carica, sfavoriscono l’accessibilità del solvente 
alla superficie peptidica e inducono una organizzazione strutturale, che è di tipo α 
 Abbreviazione Sequenza peptidica 
PrP[173-195] Ac-NNFVHDCVNITIKQHTVTTTTKG-NH2 
PrP[173-195]D178N Ac-NNFVHNCVNITIKQHTVTTTTKG-NH2 
PrP[180-195] Ac-VNITIKQHTVTTTTKG-NH2 
PrP[180-195]H187A Ac-VNITIKQATVTTTTKG-NH2 
A 
PrP[173-179]                           Ac-NNFVHDC-NH2 
Fluo-PrP[173-195] Fluo-βANNFVHDC(Met)VNITIKQHTVTTTTKG-NH2 
Fluo-PrP[180-195] Fluo-βAVNITIKQHTVTTTTKG-NH2 
Fluo-PrP[106-126] Fluo-βAKTNMKHMAGAAAAGAVVGGLG-NH2 B 
Fluo-βA[25-35] Fluo-βAGSNKGAIIGLM-NH2 
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elicoidale, nel caso del peptide PrP[180-195]H187A, o di tipo β, nel caso del peptide 
PrP[180-195]. 
 
3) Titolazioni CD ed NMR dei peptidi PrP[173-195] e PrP[173-195]D178N in 
presenza di cationi metallici bivalenti. 
L’indagine strutturale dei frammenti wild type e dell’analogo D178N in presenza di 
Zn2+ e Cu2+ non ha evidenziato alcuna interazione specifica fra i cationi metallici ed i 
peptidi prionici. I nostri risultati dimostrano che i domini C- ed N-terminale giocano 
ruoli differenti nella conversione della proteina prionica e forniscono ulteriore 
supporto ai dati di letteratura preesistenti che individuando in quello N-terminale il 
target naturale dell’interazione di PrP con i metalli [11, 12]. 
 
4) Studio integrato spettroscopico e computazionale sull’interazione fra l’antibiotico 
tetraciclina (TC) e i peptidi dell’elica α2, allo scopo di verificare l’ipotesi che la 
tetraciclina possa interagire con la parte N-terminale di PrP, come è stato in 
precedenza dimostrato [13], e contemporaneamente con il tratto C-terminale 
dell’elica α2, intercalandosi fra queste due regioni strutturalmente instabili della 
proteina (Figura 1). Si è infatti ipotizzato che, nel contesto della struttura 
tridimensionale della proteina, l’elica α2 sia spazialmente adiacente al frammento 
106-126 della parte N-terminale di PrP, precedentemente indicato come capace di 
interagire con la TC. I nostri risultati sono stati validati estendendo l’analisi anche al 
frammento PrP[106-126] ed al peptide βA[25-35], derivante dal β-Amiloide[1-42], 
opportunamente scelto per le caratteristiche amiloidi che lo accomunano ai peptidi 
prionici.  
Abbiamo dimostrato quindi che l’antibiotico ha una forte affinità nei confronti di 
peptidi derivati dell’elica α2 e che l’interazione interessa soprattutto la sua parte C-
terminale, della quale era stata precedentemente ipotizzato un possibile 
coinvolgimento nella formazione di strutture di tipo β [14]. TC potrebbe quindi 
stabilizzare tale tratto di PrP prevenendo la sua conversione strutturale e la 
conseguente aggregazione.  
 
 
 
Figura 1 Modello molecolare ottenuto per simulazione dell’interazione della tetraciclina (blu) con 
l’estremità N-terminale della PrP e la parte C-terminale dell’elica α2 (evidenziata in verde). 
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5) Analisi dell’affinità dell’elica α2 nei confronti di costrutti peptidici disegnati a partire 
dalla  struttura a raggi X del complesso fra ovPrP ed un anticorpo Fab (Figura 2) 
[15]. I costrutti peptidici (composti JMV riportati in Tabella 2) sono stati sintetizzati 
unendo con spacers di differente lunghezza, rigidità e natura chimica, i due 
frammenti peptidici Fab[30-35] e Fab[46-53] (TNYGMN e RLIYLVSR, 
rispettivamente) capaci di formare legami idrogeno con la parte C-terminale dell’elica 
α2 nel struttura cristallografica Fab-ovPrP. L’interazione dei composti JMV con il 
peptide PrP[173-195] funzionalizzato con fluoresceina è stata poi analizzata 
mediante spettroscopia di fluorescenza. Dall’analisi è emerso che tutti i costrutti 
peptidici JMV sono capaci di legare fortemente il tratto peptidico 173-195 
suggerendo che la loro affinità per tale tratto sia scarsamente correlata alle 
dimensioni, alla rigidità ed alla natura chimica degli spacers.  
 
 
 
 
Figura 2 (Sinistra) Overview del complesso. (Destra) Ingrandimento della regione di interazione. Per 
chiarezza, solo gli atomi che interagiscono attraverso legami idrogeno (linee tratteggiate) sono 
rappresentati nel formato “stick” [15]. 
 
 
 
 
 
L’insieme dei risultati ottenuti sul panorama conformazionale dell’elica α2 dimostra 
che questo dominio gioca un ruolo di fondamentale importanza nel meccanismo di 
misfolding della proteina prionica. La forte sensibilità dell’elica α2 a modifiche 
dell’intorno chimico ed a singole mutazioni amminoacidiche conferma infatti il 
carattere ambivalente di tale tratto peptidico, rendendolo un importante bersaglio per 
nuove strategie terapeutiche e diagnostiche. Inoltre, riguardo allo studio di molecole 
capaci d’interagire con l’elica α2, i nostri risultati aprono importanti prospettive per 
l’uso diagnostico e farmacologico della TC e dei costrutti sintetici JMV nelle TSE. 
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      Tabella 2 Abbreviazione e struttura dei costrutti peptidici JMV. 
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RESUME 
 
 
Un grand nombre de pathologies humaines, du diabète de type II à la maladie de 
Parkinson et la maladie d'Alzheimer, est associé à l’agrégation de protéines résultant 
d’un repliement anormal. Malgré son importance biologique fondamentale, peu de 
choses sont connues sur les processus physiologiques qui conduisent à 
l'accumulation de ces protéines. Les encéphalopathies spongiformes transmissibles 
(TSE), plus connues sous le nom de maladies du prion, appartient à cette classe. 
Elles sont toutes caractérisées par une dégénération neuronale progressive. Dans 
presque tous les cas, il y a une forte accumulation extracellulaire d'un conformère 
amyloïdogénique de la forme cellulaire normale de la protéine prion (PrPC), appelé 
scrapie isoform (PrPSc). Cette forme est probablement responsable de la  maladie. 
PrP est une glycoprotéine ubiquitaire de 231-aminoacides acide dont le rôle 
physiologique n’est pas encore connu. Les structures montrent une région N-
terminale non-structurée et un domaine globulaire C-terminal caractérisé par la 
présence de trois hélices α (α1, α2 et α3), de deux brins β courts et d'un pont 
disulfure entre Cys179 et Cys214, qui relie les deux hélices α2 à α3 et confère la 
stabilité structurale. Aujourd’hui, est acceptée l’hypothèse que la protéine possède 
une ou plusieurs régions de fragilité conformationelle qui entraine une déstabilisation 
totale de la structure secondaire et tertiaire de la protéine en fonction du changement 
de pH, des propriétés rédox du milieu et de l’état de glycosylation. La partie C-
terminale de l'hélice 2, contenant quatre thréonines adjacentes est soupçonnée 
d’être une de ces régions  et, à cet égard, elle fait l’objet de nombreuses études. 
Comme l’hélice α2 possède un comportement conformationnel ambivalent et 
plusieurs points de mutation associés aux pathologies TSE, elle constitue un modèle 
de choix pour étudier les déterminants structuraux du misfolding de PrPC et pour 
concevoir de façon rationnelle de nouveaux composés à visée thérapeutique. Les 
propriétés structurales particulièrement intéressante de ce domaine de la protéine 
PrP, nous a incité à étudier ses caractéristiques conformationnelles. Pour cela, nous 
avons synthétisé par SPPS l’hélice α2 de hPrP et divers fragments peptides de cette 
hélice. Nous les avons ensuite caractérisé par CD et par RMN en solution aqueuse à 
différents pH, dans des milieux structurants (SDS et TFE) et en présence d'anions et 
de cations métalliques bivalents. La neurotoxicité de ces peptides a également été 
testée sur des cellules de neuroblastomes B104. L’ensemble des résultats suggère 
fortement que l'hélice α2 joue un rôle important dans la conversion de la PrPC en 
PrPSc. De plus, l'affinité de l’hélice α2 et de certains de ces dérivés pour des 
molécules organiques et des pseudopeptiques que nous avons synthétisés a été 
étudié par analyse spectroscopique (CD et fluorescence) et par analyse 
computationnelle (dynamique moléculaire et docking). En particulier, nous avons 
montré que l'antibiotique tétracycline peut fortement interagir avec l’hélice α2 et que 
l'interaction concerne des résidus dans sa partie C-terminale, précédemment 
suggéré comme un bon candidat pour étudier la transition locale α→β. Enfin, les 
résultats concernant l'interaction entre l’hélice α2 et les composés synthétisés, 
conçus à partir de la structure cristallographique d’un complexe Fab-ovPrP offrent 
des outils pour localiser les régions/résidus potentiellement importantes pour la 
conversion PrPC→PrPSc et les réarrangements conformationels impliqués dans la la 
forme spongiforme de la protéine prion. 
De plus, ils ouvrent des perspectives intéressantes pour l’utilisation de ce type de 
molécules dans le diagnostic ou le traitement des maladies associées à la PrP. 
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INTRODUCTION 
 
 
I.1. Conformational diseases 
 
An increasing family of neurodegenerative disorders such as Alzheimer's, 
Parkinson's and Huntington's diseases, transmissible spongiform encephalopathies 
(TSE) and cystic fibrosis are currently classified as conformational diseases, which is 
a family of disorders where cellular functions are compromised because of protein 
misfolding and aggregation [1]. 
Since all members of this family of diseases are linked to a mechanism of aberrant 
protein folding, knowledge of the three-dimensional structure of the proteins 
implicated, both in their healthy and in their pathological forms, is the prerequisite for 
understanding the mechanism of aggregate formation and, eventually, preventing it. 
Yet, only relatively limited structural information is currently available. It is believed 
that the pathogenesis of these diseases is to be ascribed to reduced or lacking 
efficiency of physiological quality control systems, which leads to the formation of 
toxic protein aggregates, possibly affecting cellular function and eventually causing 
neuronal death [2]. Evidence has been accumulated that these aggregates possess 
various supramolecular architectures and, in most cases, form insoluble fibrillar 
deposits with well-defined structure, called amyloids [3]. A causative link between 
aggregation and disease is not, however, universally acknowledged, because 
amyloid fibril formation might be simply the consequence of a pathogenetic 
mechanism that could reside in causes to be identified [2]. The most widely accepted 
explanation for aggregation and amyloid formation is that the native fold of a protein 
isomerizes to an improperly folded conformation prior to a structural reorganization 
resulting in protein aggregation and deposition. Fibrils are not toxic in themselves, 
but the quick β-strand-bonding-driven autolinkage of polypeptide chains may easily 
cause further linkage that leads to insoluble macrostructures with inflammatory or, 
more in general, toxic properties [4, 5].  
The term amyloidosis applies when deposition of such macrostructures in the tissue 
is a dominant, histologically apparent feature [6]. Amyloidosis is characterized by the 
accumulation of abnormal proteinaceous deposits in cell compartments and/or within 
the extra-cellular matrix, in which amyloid fibrils share a cross-β core structure [3, 7]. 
Amyloid formation can also occur when the plasma concentration of normal proteins 
is persistently increased, as with acute-phase proteins and immunoglobulins in 
chronic inflammation [5].  
Such structural rearrangements likely take place in a class of degenerative 
neurological disorders involving the host-encoded prion protein (PrP), which are 
usually identified as TSE [8-10]. The general features of prion diseases are common 
to other amyloid disorders [2], underlining the interest for the prion protein as useful 
model to provide the bases for a comprehensive evaluation of protein misfolding 
mechanism. 
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I.2. Prion protein structure 
 
 
The mammalian PrP gene encodes the PrPC protein as a 253 aminoacid polypeptide 
chain from which the first 22 aminoacids (signal peptide) are cleaved shortly after 
translation commences (Figure I.2.1). Post-translational processing adds a C-
terminal glycosylphosphatidylinositol (GPI)-anchor at residue 230, which facilitates 
glycolipid linkage of PrPC to the cell membrane [11]. Recent studies on an 
anchorless, secreted version of PrPC, expressed in transgenic mice, have clarified 
that membrane anchoring is a crucial prerequisite for prion toxicity resulting in clinical 
TSE [12]. Two N-linked glycosylation sites are located at residues 181 and 197. A 
nonapeptide followed by four identical octapeptide repeats are normally located 
between residues 51 and 91.  
 
23 60 91 120 231
PHGGGWGQ PHGGGWGQ PHGGGWGQ PHGGGWGQ
GPIS―S
181 197
αβ β α α
113
 
 
Figure I.2.1 Diagram indicating secondary structure and other features of the prion protein (PrP). The 
C-terminal domain (red) contains three α-helical segments, two short β-strands, a disulfide bond, and 
a glycosylphosphatidylinositol (GPI) anchor that tethers PrP to the membrane surface. The N-terminal 
segment, up to approximately residue 120, is largely unstructured and contains the octarepeat domain 
(blue) and a hydrophobic region (green). 
 
 
 
As schematically depicted in Figure I.2.2, the structure of ubiquitous benign cellular 
form of PrP consists of an unstructured tail encompassing residues 23–125 and a 
globular domain, stabilized by an intramolecular disulfide bond (Cys179-Cys214) [13]  
and comprising residues 126–231, with a structure made of three α-helices and a 
short β-sheet. 
In a series of studies Wüthrich and co-authors have reported the NMR structure of 
the globular C-terminal domain of recombinant human PrPC (hPrPC), also 
investigating several recombinant prion proteins from other species [14-20]. The 
overall structural organization of these PrPs is very similar, with residues 128-131, 
144-154, 161-164, 173-195 and 200-228 forming the β-strand 1, the α-helix 1, the β-
strand 2, the α-helix 2 and the α-helix 3, respectively. Crystallographic studies lend 
support to this monomeric structure, but in the dimeric form, an unusual domain 
swapping of α-helix 3 is apparent, with creation of a novel short anti-parallel β-sheet 
segment at the molecular interface [21].  
As a consequence of a post-translational process, PrPC is converted into the 
aberrantly folded and disease-specific scrapie isomer, PrPSc, through a process 
whereby a portion of its predominantly α-helical structure is refolded into β-sheet [8]. 
PrPSc exhibits resistance to proteinase K digestion [22, 23]. It is also known that the 
conversion of PrPC into PrPSc, whose high β-sheet content is an essential constituent 
of putatively infectious prions [8, 24, 25], can also intrinsically occur as a result of a 
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genetic mutation, as in rare familial encephalopathies. More disturbingly, however, 
transgenetic studies argue that inoculated PrPSc can impart conformational variability 
to normal prions, thus triggering PrPC refolding into a nascent PrPSc [8]. It can be 
concluded that mechanisms that underlie pathological transitions remain unclear, 
despite attention paid to their understanding, because the highly aggregated state 
has hampered elucidation of the PrPSc structure at the atomic level. 
 
 
 
Figure I.2.2 Cartoon of the hPrP structure. The sketch was drawn according to current information 
[13]. Most salient residues are indicated by arrows. 
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I.3. Determinants of PrPC conversion: the N-terminal region 
 
 
The neurodegeneration observed in spongiform encephalopathies is believed to be 
mediated by partially protease-resistant forms of PrP. In fact, the neuropathological 
changes observed in prion disease are caused, at least in part, by the accumulation 
of proteinase K-resistant PrPSc [21-23]. This view is supported by the observation 
that the partially protease-resistant core of PrPSc displays a variety of pathogenic 
effects in vitro, including neurotoxicity and the ability to interact with plasma 
membrane, conferring an increased microviscosity. PrPSc accumulates in the central 
nervous system of affected individuals, and its partially protease-resistant core 
aggregates extracellularly into amyloid fibrils. The process is accompanied by nerve 
cell loss, whose pathogenesis and molecular basis are not well understood. 
Frankenfield and co-workers [26] compared the in vitro aggregation of a truncated 
portion of the prion protein (PrP[90–231]) and a full-length version (PrP[23–231]), 
which can be distinguished from the truncated protein because it contains the largely 
unstructured N-terminal region in addition to the α-helical C-terminal one. They found 
that the full-length protein forms larger aggregates than the truncated protein, which 
indicates that the N-terminal region may mediate higher-order aggregation 
processes, possibly influencing the assembly state of PrP before aggregation begins. 
Other studies [27] have confirmed that the N-terminal region has a pivotal role in the 
development of prion misfolding and aggregation. In fact, by using N-terminal 
deletion mutations of recombinant murine PrP, mPrP[51–90] and mPrP[32–121], it 
has been shown that the stability against pressure of the protein is dramatically 
reduced with decreasing N-domain length and the process is not reversible for 
mPrP[51–90] and mPrP[32–121], whereas it is completely reversible for the wild-type 
form. Moreover, the temperature-induced transition was found to lead to aggregation 
of all forms, but the deletion mutants showed higher thermal lability. Similar effects 
have been observed with a short synthetic peptide fragment encompassing residues 
106–126 of hPrP, which is toxic to cultured neurons depending on the expression of 
endogenous PrP. This synthetic peptide recapitulates several properties of PrPSc, 
including the propensity to form β-sheet-rich, insoluble and protease-resistant fibrils 
similar to those found in prion diseased brains [28]. Experimental data indicate that 
PrP[106–126] does not induce the formation of abnormal PrP species, suggesting, as 
an alternative explanation, that peptide toxicity depends on triggering alteration of a 
physiological function of PrPC [29]. In fact, the N-terminal truncated PrP is toxic only 
to neurons that lack endogenous PrP, while PrP[106–126] is toxic only to neurons 
that express the endogenous protein. The structure of PrP[106–126] is modulated by 
pH, and its β-sheet content is higher at pH 5 than at pH 7. Furthermore, in the 
presence of lipids it acquires a predominantly β-sheet conformation. Extensive 
studies were performed to understand the relationships between toxicity and 
physicochemical properties of amyloid peptides. To determine the role of the 
hydrophobic palindromic sequence in PrP[106–126] toxicity, Jobling et al. [30] have 
generated a series of mutant PrP[106–126] peptides with hydrophilic substitutions in 
the hydrophobic core. The results of these studies correlate the neurotoxic action of 
PrP[106–126] to its secondary structure and subsequent fibril-forming propensity. 
The data suggest that the hydrophobic C-terminal valines and the palindromic region 
from Ala113 to Ala120 of PrP[106–126] are involved in the folding and/or stabilization 
of a β-sheet aggregate. These findings are similar to those described for amyloid β-
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peptide aggregates and strengthen the view of a common structure-function 
mechanism of amyloid generation in spongiform encephalopathies and Alzheimer's 
disease [2]. On the other hand, on consideration that, in infectious and familial prion 
disorders, neurodegeneration is often seen without deposits of PrPSc, Gu and co-
workers [31] have shown that exposure of neuroblastoma cells to PrP[106–126] 
catalyzes the aggregation of cellular prion protein to a weakly proteinase K-resistant 
form and induces the synthesis of transmembrane prion protein, suggesting that 
neurotoxicity is mediated by a complex pathway involving transmembrane prion 
protein and not not only by deposits of aggregated and proteinase K-resistant PrP. 
  
15 
 
I.4. Determinants of PrPC conversion: the C-globular domain 
 
 
In the X-ray structure of monomeric sheep PrPC (sPrPC) were identified two potential 
loci of β-structure propagation [32]. The former locus (residues 129-131) is involved 
in an intramolecular β-sheet with residues 161-163 and in lattice contacts about a 
crystal dyad to generate a four-stranded intermolecular β-sheet between neighboring 
molecules. Modeling on the latter locus (residues 188-204) suggests that it is able to 
act as an α→β switch within the monomer. The α→β isomerization of PrP is most 
frequently observed in vitro in the pH range from 4 to 7 [33-37] and has been 
postulated to be induced in vivo by the low pH of endosomal compartments [38]. A 
comparison between the C-terminus crystal structures of monomeric sPrPC and 
dimeric hPrPC showed that the dimer results from the swapping of the C-terminal α-
helix 3 and rearrangement of the Cys179-Cys214 disulfide bond. An interchain two-
stranded antiparallel β-sheet is formed at the dimer interface between the 
corresponding crystal-symmetry-related residues 190-194, which are located in α-
helix 2 in the monomeric NMR structures [21]. The segment 188-201 
(TVTTTTKGENFTET) is invariant across a wide variety of species [39] and, on the 
basis of its primary structure, several features emerge that might drive PrPC 
reorganization. In particular, the seven threonine residues could confer the necessary 
conformational plasticity. Moreover, residues 188-201 in hPrP adopt an architecture 
that appears to be of lower stability as compared to the rest of the structure. The high 
intrinsic β-propensity of four adjacent threonines [40] makes this segment a good 
candidate to promote a local α→β transition, which, under suitable conditions, could 
lead to PrPSc formation, even independently of disulfide bridge rearrangement, since 
PrPSc monomers are not linked by intermolecular disulfide bonds. Furthermore, PrPSc 
can induce the conversion of the disulfide-intact form of the monomeric cellular prion 
protein to its protease-resistant form without the temporary breakage and subsequent 
re-formation of the disulfide bonds in cell-free reactions [41]. From the above studies, 
it emerges that quite small conformational adjustments can convert the monomeric 
PrPC into a potentially oligomeric nucleating unit. It is likely that some conformational 
weaknesses converging on the sequence 190-195 or a shorter surrounding region 
are able to affect the whole protein architecture and promote the non-covalent 
association of misfolded monomers. It has been also proposed [32] that the 
synergical propagation of β-sheet association involving the whole molecule mediates 
protein oligomerization. Recently, Thompson and co-authors [4] have investigated 
the conformational and aggregation behaviour of synthetic peptides corresponding to 
PrPC helices in aqueous solutions. The fragment corresponding to α-helix 1 exhibited 
a random coil CD spectrum at any pH value from 3 to 12, whereas in 40% 
trifluoroethanol (TFE) the peptide was 20% helical and did not aggregate over time 
neither did it form amyloid fibrils. However, it has been also shown that α-helix 1 
possesses a remarkably high instrinsic α-helical propensity [42] and retains 
significant helicity under a wide range of conditions, such as high salt, pH variation, 
and presence of organic co-solvents [43]. Because of its high stability against 
environmental changes, helix 1 is unlikely to be involved in the initial steps of the 
pathogenic conformational change and it could unfold in the late stage of the 
structural transition as a consequence of global conformational rearrangements 
occurring in other parts of the prion protein [43]. The fragment corresponding to α-
helix 2 underwent a time dependent β-sheet rearrangement with formation of 
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aggregates over time. However, electron microscopy showed that aggregates taken 
from CD samples were organized in fibrils, which were small at pH 7.2, but longer 
and more distinct at higher pH values. The fragment corresponding to α-helix 3 also 
underwent pH dependent β-sheet formation. The CD curve exhibited random 
organization at pH 6.0 and 7.2, and β-sheet at pH 3, with an aggregation dependent 
intensity decrease after 24 hours. The precipitate did not show fibril formation 
indicating that this peptide is not truly amyloidogenic under the conditions studied. As 
can be concluded from these observations, the relationship between 
amyloidogenicity and neurotoxicity remains unclear, because the fact that a peptide 
is somehow prone to aggregate and readily form a β-sheet structure does not 
necessarily imply that it forms amyloid fibrils. Additional evidence indicates that an 
intermediate along the pathway to fibril formation could cause toxicity, whereas large 
fibrils may not be toxic in themselves. Gallo and coworkers [44] have recently 
reported that the conserved capping box (Thr199-Glu200-Thr201-Asp202) and, in 
part, the ionic bond formed between Glu200 and Lys204 render the PrPC segment 
corresponding to the α-helix 3 structurally autonomous, in contrast to α-helix 1 and α-
helix 2 peptides. In fact, the D202N capping mutation associated to the Gerstmann-
Straussler-Scheinker (GSS) disease almost completely destabilizes the isolated α-
helix 3 peptide, thus possibly initiating the PrPC pathogenic process associated with 
this substitution. Moreover, cell culture data based on the NMR structure of mouse 
PrPC suggest that the highly conserved hydrophobic side chain at residue 204 of α-
helix 3 is required for folding and maturation of PrPC, providing an essential 
stabilization of α-helix 1 structure by interacting with Phe140, Glu145, Tyr148, and 
Tyr149. Disruption of α-helix 1 prevented attachment of the GPI anchor and the 
formation of complex N-linked glycans. In the absence of a C-terminal membrane 
anchor, however, α-helix 1 induced the formation of unglycosylated and partially 
protease-resistant PrP aggregates [45]. This result is confirmed by molecular 
dynamic simulations, in which disturbances of the folding and maturation process of 
PrPC have been interpreted as consequences of mutation-induced structural changes 
in PrP, involving α-helix 1 and its attachment to α-helix 3 [46]. A number of results on 
cellular toxicity [4], fibrillization capabilities [13], and metal binding properties [47] of 
synthetic variants of the α-helix 2 point to an important contribution of this region to 
the overall biological behaviour of the prion protein. In fact, perturbations leading to 
structural rearrangements that may strongly affect the stability of the α-helix 2 could 
involve deglycosylation of Asn181 [13] and/or copper binding to His187 [47]. 
Rearrangements of the α-helix 2 could promote β-sheet-mediated protein association 
leading to a further α→β transition and subsequently to aggregation. In a novel 
thermodynamic study, the α→β conversion of the N- and C-termini blocked fragment 
corresponding to the α-helix 2, PrP[173-195], has been characterized by measuring 
α-helical and β-structure formation propensities in the temperature interval from 280 
K to 350 K [48]. The thermodynamic cycle reported in Figure I.4.1 shows that the two 
ordered conformations were found to be separated by 5-8 kJ/mol, with an entropic 
advantage of 0.04 kJ mol-1 K-1 favoring the α-helical organization. This subtle free 
energy difference was interpreted as denoting the chameleon-like character of 
PrP[173-195], which could be governed, in the protein, by the cellular 
microenvironment, according to the finding that slight conditional changes may cause 
chameleon sequences to fold into either α- or β-structure [49]. In this context, it is 
worth noting that, in the whole PrPC, the close packing of the first three turns of the α-
helix 2 against the α-helix 3 generates a complementary interface [17, 21] that 
strongly stabilizes the helix up to around residue 188, with the glycosyl moiety bound 
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to Asn181 providing further stabilization [13]. Conversely, the region spanning 
residues 190-195 is rather apart from the α-helix 3, which is well characterized only 
up to Thr219 in the NMR structures of mouse PrPC [50] and found in β-conformation 
in the dimeric crystal structure of hPrPC [21], suggesting that this site is one of the 
most prone to structural rearrangements upon suitable perturbation. Thus, the short 
C-terminal end of the full length α-helix 2 could be involved in the nucleation process 
of prion misfolding and oligomerization, possibly in cooperation with the N-terminal 
fragment 82-146, whose intrinsic properties are dependent upon the integrity of the 
C-terminal region [51].  
 
 
 
Figure I.4.1 Thermodynamic diagram of structural preferences of PrP[173–195] (α-helix 2). 
Extrapolated values of ∆G° for the random-to-α and random-to-β transitions are plotted as a function 
of temperature. The dashed line represents the thermodynamics of the α→β transition as obtained by 
difference between the ∆G°'s of the two random-to-ordered structure transitions. All experimental data 
were fitted to straight lines because neither transition is accompanied by an appreciable heat capacity 
change, suggesting that enthalpy and entropy changes are independent of temperature [48]. 
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I.5. Binding by metal ions 
 
 
Research over the past few years clarified that PrPC can exist in a Cu-metalloprotein 
form in vivo [52] and displays high selectivity for Cu2+ [53, 54]. Screens against other 
divalent cations, such as Ca2+, Co2+, Mg2+, Mn2+ and Ni2+, failed to find high-affinity 
interactions. In order to extract functional information, many efforts have been 
devoted to the structural characterization of Cu2+ binding sites [49, 52-66]. The 
emerging consensus is that most copper binds in the octarepeat domain, comprising 
the HGGGW segment as the fundamental unit involved in Cu2+ coordination [67, 68]. 
The crystal structure of the complex reveals equatorial coordination of Cu2+ by the 
histidine imidazole, two deprotonated glycine amides, and a glycine carbonyl, along 
with an axial water bridging to the Trp indole, consistently with companion 
experiments in solution [68]. This somewhat unusual copper binding site is by no 
means unprecedented. In most copper binding proteins, side chain moieties such as 
histidine imidazole or cysteine thiol enter into contact with the metal ion [69]. 
Previous studies showed that unstructured peptides containing histidines coordinate 
in a fashion similar to that now identified for PrP [70, 71]. The pKa of amide protons 
is typically 13–15, and consequently the amide nitrogen is not ionized at pH 7. 
However, nitrogen and Cu2+ are well matched on the hard-soft scale of Lewis acid–
base interactions. Thus, with the histidine imidazole anchoring the metal ion close to 
the polypeptide backbone, Cu2+ may be uniquely able to displace a nearby amide 
proton at physiological pH [72]. Modeling, EPR and companion spectroscopic studies 
on peptides as well as full length protein provide however evidence that additional 
copper sites are located in the region connecting the unstructured N-terminal 
segment to the C-terminal globular portion of PrP [58, 59, 66]. Accordingly, it has 
been proposed that an additional copper-binding site compared with the four of the 
octarepeat domain binds around His 96 and/or His 111, a region of the PrP molecule 
known to be crucial for prion propagation [55, 73-75]. In fact, proteolytic cutting of 
PrPSc at approximately residue 90 does not result in loss of infectivity. This suggests 
that the octarepeat domain, and hence copper, do not play a role in TSEs and may 
not be necessary to PrP conversion and disease, but a modulating role in kinetics 
and pathology cannot be excluded. Indeed, the octarepeat domain and copper have 
been directly implicated in neurological disease [55]. Finally, recent studies show that 
binding of a single copper rapidly and reversibly induces PrPC to become protease-
resistant and detergent-insoluble [76]. There is experimental evidence that binding 
takes place at His96 in full-length PrP, that is outside both the octarepeat and the C-
globular domains [53, 74, 75]. The amyloidogenicity and neurotoxicity of PrP[106-
126] are common to the Alzheimer’s disease amyloid β peptide. Given that the 
biophysical behaviour and activity of amyloid β peptide are governed by transition 
metals, the effect of metals has been also studied on PrP[106-126]. The fibrillization 
of this peptide is completely inhibited in a metal-depleted buffer, and Cu2+ and to a 
lesser extent Zn2+ have been found to restore its aggregation [64]. The metal binding 
site was found to comprise the N-terminal amino group, His111 and Met112. This 
supports the view of a common structure-function mechanism of amyloid generation 
in spongiform encephalopathies and Alzheimer’s disease [43–45]. Most recently, the 
stimulatory potential of Cu2+, Mn2+, Zn2+, and Al3+ in inducing defective 
conformational rearrangements which trigger aggregation and fibrillogenesis has 
been investigated in the recombinant hPrP fragment spanning residues 82-146 [77]. 
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This region has been identified as a major component of the amyloid deposits in the 
brain of patients affected by GSS disease. Amino acid substitution in the neurotoxic 
core (sequence 106-126) reduced its amyloidogenic potential. However, alteration of 
the 127-146 sequence, which comprises a segment of the C-terminal globular 
domain, also caused strong inhibition of the fibrillogenesis, thus suggesting that 
integrity of this region was essential both to confer amyloidogenic properties on GSS 
peptides and to activate the stimulatory potential of the metal ions. Notably, only a 
few studies have been carried out on metal interaction with peptides derived from the 
C-terminus of PrP, which contains the histidine residues (H140, H177 and H187) and 
the helical region. Recent spectroscopic experiments [47, 78] exclude the 
involvement of H140 in Cu2+ binding, but the aggregation of model peptides 
hampered characterization of the metal interaction with H177 and caused uncertainty 
about Cu2+ binding to His 187 at physiological pH. Incidentally, it has been found [79, 
80] that the only known histidine variant associated with familial encephalopathy 
could be associated with the H187R mutation in the PrP gene. Brown and co-authors 
[47] characterized Cu2+ complexes with two analogues of the peptide fragment 180-
193 (VNITIKQHTVTTTT), which almost entirely encompasses the PrPC’s α-helix 2, 
one with blocked and the other with free C- and N-termini. They analyzed the 
involvement of His in the interaction with Cu2+ at pH values close to neutrality. The 
different histidine side-chain anchoring in the two peptide forms and the formation of 
different Cu2+ complex species were attributed to the competition between the amino 
and imidazole nitrogens in their binding to the metal ion. However, the significant 
increase of toxicity of the N- and C-termini blocked peptide upon Cu2+ addition was 
unclear and interpreted as likely reflecting the effect of the different coordination 
environment on the conformation of the peptides. Other studies on α-helix 2-derived 
peptides [4] showed that PrP[178-193] and PrP[180-193] are the only ones able to 
form amyloid. Exposure to copper ions resulted in a significant increase of PrP[178-
193] neurotoxicity as compared to the metal control. The peptide was also found to 
promote Cu(II)-induced lipid peroxidation and cytotoxicity in primary neuronal 
cultures. On the other hand, PrP[198-218], which can form β-sheet aggregates but 
does not form fibrils, showed no copper-induced neurotoxicity. In conclusion, most 
data suggest that copper ions may play a role in toxicity of amyloidogenic and/or 
fibrillogenic proteins, also indicating that a region of PrPC other than PrP[106-126] 
may be involved in neurotoxicity.  
  
20 
 
I.6. PrP Biology 
 
 
In the most accredited model of prion formation and replication, a direct interaction 
between the pathogenic PrPSc template and the endogenous PrPC substrate is 
proposed to drive the formation of nascent infectious prions in the case of infectious 
diseases [8]. Characterizing the exact intracellular localization of PrPC and PrPSc is 
important for identifying the intracellular compartment and the mechanism that 
underlie prion formation. The possibility that misfolding and/or misfuction of PrPC 
correlate with defects in its trafficking is supported by several studies in which the 
intracellular localization of some inherited pathological PrP mutants have been 
shown to be altered [81]. It is not yet clear, however, whether mislocalization is the 
cause or the effect of prion misfolding and/or misfunction [82]. Consequentely, it is 
important to understand the relationships between the intracellular trafficking, proper 
protein misfolding and function of PrPC (Figure I.6.1) [83]. 
 
 
 
Figure I.6.1 Intracellular trafficking of PrPC and PrPSc and possible patways of PrPSc formation [83].  
 
PrPC is synthetized in the rough endoplasmic reticulum (ER), where simple N-linked 
oligosaccharides and the GPI-anchor are added, and it arrives at the cell surface 
after transiting the Golgi apparatus where further oligosaccharide modifications take 
place. Most PrPC is transported to the cell surface where it is predominantly located 
in specialised detergent-resistant microdomains (DRM) known as rafts or caveolae 
[84]. Findings of transfected-cell studies indicate that wild-type PrP cycles between 
the cell surface and an early endocytic compartment, via an association with clathrin-
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coated pits [85], but also can migrate to late endosomes or lysosomes via non-
classic, caveolae-containing endocytic structures, apparently completely bypassing 
clathrin-related endocytic mechanisms [84]. Such variations in PrPC endocytic 
trafficking could indicate the cell type in which exogenous PrP was expressed [86]. 
Disturbances in normal intracellular trafficking of PrPC can culminate in its retrograde 
transport through the Golgi apparatus, with heightened accumulation of PrPSc in the 
endoplasmic reticulum. The site of PrPC→PrPSc conversion is uncertain. DRM [85] 
and the endosomal pathway [87] are possible sites for transformation. The 
endoplasmic reticulum may participate too, especially in familial TSE [88]. DRM could 
be important sites for initial PrPSc propagation during intercellular spread, because 
membrane-associated conversion seems to need insertion of PrPSc into the cell 
membrane, possibly by exchange of membrane particles or by GPI-anchor-
dependent painting. Cell-free conversion models show the need for physical 
contiguity when different membrane components harbour PrPC and PrPSc [89]. Other 
aspects of normal PrPC cell biology may be closely related to pathogenesis. PrPC has 
a half-life of only 5 h or so, and up to 10% of newly synthesised protein might be 
retrogradely transported from the endoplasmic reticulum to the cytosol, where it 
undergoes degradation [90], although conflicting results have been reported [91]. 
PrPC synthesis followed by degradation and clearance of misfolded protein seem to 
be finely balanced functions, since incorrectly folded conformers are not detected 
under usual conditions. Manipulation of synthesis and degradation pathways has 
indicated possible mediators of PrP-related toxic effects and highlighted the 
complexity of the system. Perturbation of proteasome function results in wild-type 
PrP accumulation in the cytoplasm, which correlates with toxic effects in vulnerable 
cell lines and neurodegeneration in transgenic mice, without PrPSc formation [92]. 
However, findings of subsequent studies suggest that cytoplasmic accumulation of 
PrPC may indicate an absence of translocation of the nascent PrP peptide to the 
endoplasmic reticulum under conditions of increased PrP expression rather than 
retrograde transport [91]. Nonetheless, PrP, harbouring mutations associated with 
familial TSE, accumulates in the endoplasmic reticulum [88] and cytoplasm in the 
absence of proteasomal inhibition. PrP accumulating in the cytosol forms aggregates, 
which acquire some properties of PrPSc, and, once present, persist despite only 
transient proteasome inhibition [93]. This occurrence suggests that PrP, by contrast 
with other proteasomaly degraded proteins, could have a unique innate ability to 
promote and sustain its own conformation change. Importantly, in vitro toxic effects 
did not correlate with appearance of PrPSc [93]. Data of this type suggest a generic 
mechanism underlying age-related neurodegenerative diseases, wherein 
compromise of quality control of endoplasmic reticulum protein synthesis from 
whatever cause allows harmful soluble conformers to accumulate. Once present, 
PrPSc seems to serve as a template for conversion of PrPC to the abnormal disease-
associated form, in a cyclic autocatalytic amplification, needing at least temporary 
dimerisation of the two isoforms. This template property of PrPSc, shown in a cell-free 
conversion assay [94], has replicated in vitro many of the species and strain 
characteristics noted in TSE. The precise in vivo mechanism by which PrPC is 
converted to PrPSc remains to be clarified, but a stepwise transformation and 
acquisition of altered biophysical properties seems most likely, with folding 
intermediates, including molten globule forms [85, 22]. 
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I.7. Approaches to TSE  therapy 
 
 
Anti-prion compounds 
 
Devising approaches to the therapy of TSE, is beset by many difficulties. First of all, 
the nature of the infectious agent is understood only in outline, and its composition, 
structure, and mode of replication are still shrouded in mystery. In addition, the 
mechanism of pathogenesis is not well understood. And finally, because the disease 
is usually recognized only after onset of severe clinical symptoms, only the preclinical 
diagnosis of TSE would permit the prevention (or delay) of neurodegeneration. 
On the basis of the present knowledge on prion diseases, potential therapeutic 
strategies are: to stabilize the structure of PrPC via the formation of a PrPC-drug 
complex; to prevent the formation or induce the degradation of amyloid aggregates; 
to hinder the conversion process or bind to PrPSc; to destabilize the PrPSc structure or 
interfere with the cellular uptake of PrPC/PrPSc. Currently, no effective treatment 
exists, and the development of novel therapeutic strategies against prion diseases 
has become a priority. Various studies have shown that compounds with properties 
that interfere with fibrillogenesis may be of therapeutic and prophylactic interest. 
Thus, different classes of drugs have been described to interfere with the formation 
of PrPSc in scrapie–infected cell lines or animal models. All these compounds, 
including sulphated polyanions [95-97], acridine-based compounds [98, 99], 
tetrapyrroles (e.g., porphyrines, phtalocyanines) [100], the sulfonated azo-dye Congo 
red and some of its synthesized derivatives [97, 101, 102], antibiotics (e.g., 
amphotericin B derivatives) [103], branched polyamines [104, 105] and synthetic 
peptides [106], have been investigated for their ability to prevent the conformational 
change PrPC→PrPSc or to interfere with the fibril formation of synthetic peptides. 
However, the therapeutic use of these compounds is restricted by their intrinsic 
cytotoxicity and pharmacokinetic properties, as well as by their limited ability to pass 
the blood/brain barrier.  
Recently, the anti-prion and the anti-amyloidogenic ability of the tetracycline 
antibiotics (TCs)  were shown by studies performed in vitro [28] and in vivo [107]. 
The TCs are a group of structurally-related antibiotics used to treat bacterial 
infections since the 1940s [108]. They have very similar chemical stuctures with 
twofold features: a hydrophobic interface derived from a common hydronaphthacene 
moiety containing four fused rings [109, 110] and an opposite H-bond donor-rich side 
that undergoes tautomerization depending on pH conditions [111]. 
The main features required for antibacterial activity are well estabilished [108] and, 
according to these requirements, the clinically used TCs present various substitutions 
(Figure I.7.1).  
These molecules have well characterized pharmacological and pharmacokinetic 
properties, relatively low toxicity, and some of them are efficient in crossing the 
blood/brain barrier if an appropriate treatment route is used [112]. Among the others, 
the anti-prion ability of the antibiotic tetracycline (TC) was shown by in vitro models 
[28] studying the interaction of TC with the PrP aggregates generated by synthetic 
peptides, homologues to the sequences spanning residues 82-146 and 106-126 of 
hPrP. TC has been described as able to prevent the PrP peptides aggregation, to 
reduce the protease resistance and the disruption of PrP peptide aggregates and to 
abolish the neurotoxicity and astroglial proliferation induced by PrP peptides. In an in 
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vivo study [107], TC significantly delayed the onset of clinical signs of disease and 
prolonged survival into Syrian hamsters infected with scrapie-infected brain 
homogenates. 
Moreover, NMR experiments on the 106-126 fragment of hPrP suggest that the 
hydrophobic interface of TC can interact with several residues in the N-terminal part 
of hPrP, namely, Ala 117- 119, Val 121-122, Leu 125 [113]. These residues lie within 
the well known 106-126 region, which when isolated from the context of the entire 
protein, has a high propensity to adopt β-sheet secondary structure and to form 
amyloid fibrils [28]. Further, as already discussed, the 106-126 peptide is also 
neurotoxic and induces glial cell activation in vitro [28, 114-117]. All these properties 
are strongly suggestive of a heavy involvement of this region in the protein 
pathological mechanisms. On the ground of the earlier findings, the effects of TC on 
prion diseases have been ascribed to its interaction with 106-126 hPrP fragment. 
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Compound R1 R2 R3 R4 R5 R6 
Tetracycline H CH3 OH H N(CH3)2 H 
Chlortetracycline Cl CH3 OH H N(CH3)2 H 
Demeclocycline Cl H OH H N(CH3)2 H 
Doxycycline H CH3 H OH N(CH3)2 H 
4-Epichlortetracycline Cl CH3 OH H H N(CH3)2 
4-Epioxytetracycline H CH3 OH OH H N(CH3)2 
4-Epitetracycline H CH3 OH H H N(CH3)2 
Meclocycline Cl =CH2 - OH N(CH3)2 H 
Methacycline H =CH2 - OH N(CH3)2 H 
Minocycline N(CH3)2 H H H N(CH3)2 H 
Oxytetracycline H CH3 OH OH N(CH3)2 H 
 
Figure I.7.1 Chemical structure of tetracycline and its analogues. 
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Immune intervention 
 
Given the few possibilities for therapeutic and/or prophylactic intervention to date, 
new therapeutic strategies are a major focus of research to identify new compounds 
able to block or prevent prion diseases. A promising therapy lies in the potential of 
active or passive immunization using anti-PrP antibodies. Although active 
immunization strategies are confronted with a problem of self-tolerance [118], 
polyclonal anti-PrP auto-antibodies can be induced with dimeric PrP in wild-type mice 
and interfere efficiently with PrPSc propagation in prion-infected cells [119]. In 
addition, vaccination with recombinant mouse prion protein delays the onset of prion 
disease in mice [120]. Another vaccination approach by passive immunization is also 
promising. Indeed, anti-PrP antibodies were not only shown to inhibit formation of 
protease-resistant PrP in a cell-free system [121] but were also shown to prevent 
scrapie infection of susceptible mouse neuroblastoma N2a cells [122] and inhibit 
prion replication in infected cells [123-125]. In addition, transgenic expression of the 
anti-PrP monoclonal antibody 6H4 in mice expressing PrP blocks pathogenesis of 
prion introduced by intraperitoneal inoculation [126]. The mechanism by which anti-
PrP antibodies interfere with PrPSc replication is not clear, but the main hypothesis 
presented so far involves either a perturbation of PrPC trafficking and degradation 
[124] or a disruption of the interaction between PrPC and PrPSc [123] by the 
antibodies. 
However, despite the abundance of data now available on anti-PrP monoclonal 
antibodies, their application in TSE therapy or diagnosis is limited by the poor 
knowledge on the infectious and pathological mechanisms of prion diseases and the 
exact roles of PrPC and PrPSc in the brain dysfunctions caused by TSE. Therefore, 
progress in therapy is tightly linked to a better understanding of the basic science of 
TSE. A first step in such a understanding would be to identify and structurally define 
epitopes of antibodies that cross-react with PrPC and PrPSc. This would provide 
structural information directly derived from the infectious agent and help understand 
the mechanisms of PrPSc formation and spreading in infected organisms. 
Eghiaian and co-authors [127] determined the X-ray structures of the C-terminal 
domain of three scrapie-susceptible ovine PrP variants. They have cocrystalized this 
domain with a Fab fragment that cross-react with PrPC and PrPSc and reported the 
2.5-Å-resolution crystal structure of these complexes (Figure I.7.2). The ovPrP–Fab 
structure defines the epitope of the antibody that basically consists of the last two 
turns of ovPrP helix 2, structural invariant in the human domain. This epitope is 
conserved in PrPC and PrPSc from brains of infected animals, which constitutes 
structural information on the pathological prion conformer directly derived from an 
infectious sample. 
This characterization of the interaction of OvPrPC and infectious OvPrPSc with an 
antibody have provided structural information on the PrPC→PrPSc conversion; the 
availability of additional antibodies, Fab fragments and molecules that bind to PrPC 
and/or PrPSc will allow further structural characterization of this transformation. 
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Figure I.7.2 Overview of the OvPrP–Fab complex. Fab heavy and light chains are shown in green and 
blue, respectively [127].  
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II. AIM OF THESIS 
 
 
A computational analysis illustrates that native PrP exhibits large regions of 
conformational ambivalence and suggest that it is only a marginally stable protein 
[46]. Other simulations also indicate that the conformational variability of the entire 
prion protein sequence is unusually high compared with other proteins of similar 
length [128]. Moreover, the tendency to increase the β-structure content is very likely 
an intrinsic characteristic of the prion protein fold, irrespective of thermodynamic or 
structural conditions [129]. In the C-globular domain, unusually low α-helical and β-
sheet propensities feature the segment 173-195, corresponding to α-helix 2, in spite 
of the fact that this segment retains a helical conformation in the whole protein. In 
addition, the unusually high density of disease-promoting mutations in α-helix 2 also 
points to the particular importance of this helix for conformational transition of PrP. 
More specifically, it seems reasonable that a single amino acid replacement in the 
vicinity of the α-helix 2 may significantly affect the organization of the entire α2-α3 
helical part, enhancing the propension of this region for the β-conformation and 
facilitating structural rearrangements.  
Further support to this hypothesis comes from the finding that the hPrPC mutants 
T183A and F198S, which are associated to inherited prion diseases, severely affect 
folding and maturation of PrPC in the secretory pathway of neuronal cells in vitro, 
adopting misfolded and partially protease-resistant conformations [130]. These 
pathogenic mutations interfere with folding and attachment of the GPI anchor [130]. 
Indeed, based on a refined NMR structure, it was predicted that they would 
specifically destabilize the PrP C-terminal globular domain, because they involve key 
interactions in the hydrophobic core [50]. The resulting three-dimensional 
arrangement could account for the defect in maturation and the efficiency of the GPI 
anchor attachment. The hypothesis that the segment comprising the C-terminus of α-
helix 2 and the adjacent loop may be partially unfolded and represent a potential 
oligomerization site is also supported by crystallographic data [21]. Furthermore, the 
α-helix 2 fragment, also depending on the glycosylation state and the presence of 
metals [13, 47, 131] can be toxic to neuronal cells and strongly fibrillogenic, adding a 
further clue to the working hypothesis that it is involved in the protein aggregation 
process and in the toxicity associated to the scrapie variant. 
 
    Following the thread of these arguments, we have investigated the structural 
behaviour of the α-helix 2 domain designing peptides corresponding to the α-helix 2 
of hPrP (listed in Table II.1(A)) which were characterized in aqueous buffer, in 
structuring media, in presence of ions and assayed for their in vitro neurotoxicity. 
The peptides reported in Table II.1(A), obtained in the N- and C-termini blocked form 
by solid phase peptide synthesis (SPPS), were chosen as representative contributors 
to the conformational landscape of the human prion protein helix 2 domain. The first 
two peptides, PrP[173-195] and PrP[173-195]D178N, are related to the full length α-
helical 2 region, and represent the wild type sequence and the D178N mutant, which 
is the most important mutation occurring in Creutzfeldt-Jakob Disease (CJD), 
respectively [132]. In addition, the shorter PrP[180-195] peptide and its 
complementary segment PrP[173-179] were also studied. The investigation into the 
PrP[180-195] peptide is justified by two reasons. First, it includes the threonine-rich 
region, which is characterized by strong β-sheet forming propensity [133]. Second, 
the absence of cysteine in the primary structure allowed us to exclude effects linked 
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to the reactivity of the thiol moiety. Moreover, the PrP[180-195]H187A analogue was 
chosen to investigate the role of the histidine 187 in the structural arrangement of the 
180-195 fragment and the conformational dependence of this prion segment on pH 
change with respect to the H187 protonation.  
   In particular, 
 we have undertaken a comparative CD, NMR and cellular toxicity study on 
peptides corresponding to the full length α-helix 2 of hPrP (PrP[173-195]), to the 
shorter C-terminal region (PrP[180-195]) and to the CJD-associated mutant 
(PrP[173-195]D178N), in order to shed further light on the structural properties of this 
intriguing protein domain and on the influence that a disease-associated mutation 
can have on its relative stability and toxicity;  
 we have showed how ionic strength and pH influence the conformation of the 
hPrP α-helix 2 fragment PrP[180-195] and its analogue PrP[180-195]H187A 
according to a Hofmeister-series-type dependence [134, 135]; 
 we have performed CD and NMR titrations of PrP[173-195] and PrP[173- 
195]D178N in presence of metal cations. 
 
 
  Table II.1 Code and sequence of synthetic peptides 
 
 
In a further set of experiments, three PrP fragments and another representative 
amyloidogenic peptide (see Table II.1(B)) were functionalized with fluorescein in 
order to investigate, by steady-state fluorimetry, their affinity for potential PrP-binding 
molecules. 
In detail, 
 we have performed an integrated spectroscopic and computational study of 
the interaction between tetracycline (TC) and these fluorescein derivatized α-helix 2 
petides to check the reliability of the hypothesis that TC can interact with both the N-
terminal 117-125 segment, as already demonstrated [113], and with the Thr-rich helix 
2 portion, acting as a joining moiety between two structurally unstable PrP regions. It 
has intriguingly been hypothisezed that, within the context of the prion protein 
tridimensional structure, the α-helix 2 region is spatially adjacent to the 106-126 
fragment and could be packed with this part. To increase the meaningfulness of our 
results, the same analysis has been applied to the study of PrP[106-126] and to 
another representative amyloidogenic peptide, βA[25-35], that is derived from the 
βA[1-42] [136]. 
 Code Peptide sequence 
PrP[173-195] Ac-NNFVHDCVNITIKQHTVTTTTKG-NH2 
PrP[173-195]D178N Ac-NNFVHNCVNITIKQHTVTTTTKG-NH2 
PrP[180-195] Ac-VNITIKQHTVTTTTKG-NH2 
PrP[180-195]H187A Ac-VNITIKQATVTTTTKG-NH2 
A 
PrP[173-179]                          Ac-NNFVHDC-NH2 
Fluo-PrP[173-195] Fluo-βANNFVHDC(Met)VNITIKQHTVTTTTKG-NH2 
Fluo-PrP[180-195] Fluo-βAVNITIKQHTVTTTTKG-NH2 
Fluo-PrP[106-126] Fluo-βAKTNMKHMAGAAAAGAVVGGLG-NH2 B 
Fluo-βA[25-35] Fluo-βAGSNKGAIIGLM-NH2 
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 we have identified the Fab[30-35] and Fab[46-53] fragments which are able to 
form hydrogen bonds with the α-helix 2 C-terminal end in the Fab-ovPrP X-ray 
structure (Figure I.7.2) [127] and designed peptide constructs putatively suitable to 
model the ovPrP-Fab interaction. Finally, we have investigated the interaction of the 
helix 2-derived peptide with these compounds by steady-state fluorimetry. 
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III. RESULTS 
 
 
III.1. Comparative CD, NMR and cellular toxicity study on PrP[173-195], its 
D178N analogue and the shorter PrP[180-195] segment 
 
 
CD 
 
The solution behaviour of the three hPrP peptides, PrP[173-195], PrP[173-
195]D178N and PrP[180-195], was assayed in aqueous buffer at neutral pH and in 
presence of SDS and TFE.  
As shown in Figure III.1.1, the shape of CD spectra at pH 7.0 gradually changes in 
going from PrP[173-195] to PrP[180-195]. In fact, the spectrum of the wild-type 
peptide is dominated by disordered structure, as suggested by the minimum around 
198 nm. Similarly, disordered structure is still predominant in the D178N mutant, but 
the shoulder at about 220 nm suggests an increase of β-type organization as 
compared to the wild-type peptide. Finally, the main contribution to the spectrum of 
PrP[180-195] is β-type. Additional experiments performed on PrP[173-179] dissolved 
in water showed a random organization (Figure III.1.2). Thus, it seems reasonable to 
infer that, in the presence of this segment, peptides derived from the full length α-
helix 2 (PrP[173-195] and PrP[173-195]D178N) are not able to display spectral 
characteristics that are otherwise prominent in PrP[180-195].  
 
Figure III.1.1 CD spectra at neutral pH. (--) PrP[173-195]. (--) PrP[173-195]D178N. (--) PrP[180-
195]. 
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Figure III.1.2 CD spectra at neutral pH of PrP[173-179]. 
 
 
The first set of experiments was carried out using SDS as the structuring agent, 
based on the notion that peptides may be induced into a β-sheet structure at sub-
micellar concentrations of this substance [137-139]. Actually, little is known about the 
nature of this solvent system, which has been described as a mimetic of protein 
interiors. It is presumed that the non-polar tails provide a template for the 
hydrophobic domains of peptides, mimicking the environment found in the interior of 
the parent protein, whereas the sulfate moiety keeps the β-structured peptide in 
solution. 
The addition of SDS modified the shape of the spectra of the wild-type and the 
mutant peptides into that typical of a β-type profile, with positive and negative bands 
near 195-200 nm and 216-220 nm, respectively [140]. SDS-induced transitions, as 
monitored by the signal intensity at 200 nm, are shown in Figure III.1.3. It can be 
appreciated that intensities for PrP[173-195] and PrP[173-195]D178N increase to 
final positive values that reflect the different amounts of β-type structure. It is worth 
noting that this occurs in a very narrow range of SDS concentration for PrP[173-
195]D178N.  
A similar set of experiments was carried out monitoring TFE-induced modifications of 
the far UV CD spectrum of PrP[173-195], PrP[173-195]D178N and PrP[180-195]. 
TFE is a hydrophilic and hydrogen-bonding solvent that appears to stabilize peptides 
in the secondary structure for which a given sequence has propensity [139]. It 
belongs to a group of organic substances such as methanol, ethanol, acetonitrile, 
1,1,1,3,3,3-hexafluoroisopropanol at low pH, octanol mixed with other alcoholic 
solvents, and SDS at high concentrations, which are known to induce α-helical 
organization in peptides [141-143]. TFE addition caused the spectra of wild-type and 
mutant peptide to change into an alpha-helical profile, although to a different extent, 
with pronounced minima at 208 and 222 nm and a strong positive maximum at 191-
193 nm [140], whereas PrP[180-195] underwent less pronounced spectral 
modifications, with still predominant β-type features. TFE-induced transitions, as 
monitored by the signal intensity at 222 nm, are shown in Figure III.1.4.  
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Figure III.1.3 SDS titrations. (--) PrP[173-195]. (--) PrP[173-195]D178N. (--) PrP[180-195]. The 
intensity was monitored at 200 nm. 
 
 
 
 
Figure III.1.4 TFE titrations. Symbols used for peptides are the same as reported in Figure III.1.3. The 
intensity was monitored at 222 nm. 
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NMR 
 
The CD analysis has shown that these peptide fragments exhibit random or β-type 
organization in aqueous solution. This is likely to be ascribed to absence of mutual 
interactions with the other helical segments as well as of the interhelical disulphide 
bridge, which contribute to the integrity of the whole C-terminal globular domain in 
PrPC. To avoid experimental ambiguity due to the fact that the parent segment in the 
native protein assumes helical conformation, we have mimicked native-like 
conditions using the α-inducer TFE to force the peptides to assume a conformation 
as close as possible to that observed in the cellular prion protein.  
 
 
PrP[173-195]. The bar diagram of diagnostic NOE effects, as derived from the 
NOESY spectrum in TFE at 300 ms mixing time, is reported in Figure III.1.5 Any 
ambiguity caused by the signals of the four consecutive Thr residues was overcome 
by NOESY and 1H15N-HSQC experiments. 3JNH-CH coupling constants assumed the 
very small values typical of α-helix. Weak dαN(i,i+3) medium range, strong dNN(i,i+1) 
sequential as well as strong dαβ(i,i+3) medium range effects for almost all residues are 
consistent with α-helical conformation. The 175-193 bundle of the best thirty DYANA 
structures, as obtained by best fitting of the backbone (RMSD = 1.13 ± 0.50 Å), is 
also drawn in this Figure III.1.5.  
 
 
 
 
 
Figure III.1.5 NOE effects and DYANA backbone fitting of PrP[173-195]. Connectivities were derived 
from NOESY spectra at 300 ms mixing time. Backbone NOE connectivities are indicated by horizontal 
lines between residues, with thickness indicating their relative magnitude. The first three lines below 
the amino acid sequence represent torsion angle restraints for the backbone torsion angles Φ and Ψ, 
and for the side-chain torsion angle Х1. For Φ and Ψ, a  symbol encloses secondary-structure-type 
conformation; a ▲ symbol indicates compatibility with an ideal α-helix; and a ● symbol marks a 
restraint that excludes the torsion angle values of these regular secondary structure elements. Filled 
squares of different sizes depict torsion angle restraints for Х1, depending on the number of allowed 
staggered rotamer positions. The bundle of the region 175-193 of the best 30 DYANA structures was 
obtained by best fitting of the backbone (RMSD = 1.13 ± 0.50 Å). 
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PrP[173-195]D178N. TOCSY experiments on the PrP[173-195]D178N analogue 
suggested that the replacement of Asp178 with Asn doesn’t substantially affect the 
chemical shifts. Only 0.2 ppm protonic chemical shifts of HN and the CHβ of Asn178 
as compared to Asp178 were recorded by superimposition of the two TOCSY 
experiments. Careful analysis of the NOESY spectrum highlighted effects typical of 
secondary structure essentially in the N-terminal region, even though the intensity of 
the dNN(i,i+1) ones was reduced. The dαN(i,i+1) between the H-Cα and the HN-proton of 
Gln186 and His187, respectively, suggested the local presence of an extended 
conformation in the modified sequence, strongly perturbing the central core of the 
wild type helix motif. Figure III.1.6 shows all diagnostic NOE effects and the 
superimposition of the region 175-193 of the best thirty structures obtained by 
DYANA calculations. However, the value of the backbone RMSD of 2.07±0.61 Å 
suggests the presence of several quite similar conformations. We argue that the 
negative charge of Asp178 plays a key role in forcing the entire 173-195 fragment to 
assume a full helical conformation, which would not be otherwise allowed. 
 
 
 
 
 
 
 
Figure III.1.6 NOE effects and DYANA backbone fitting of PrP[173-195]D178N. Connectivities were 
derived from NOESY spectra at 300 ms mixing time. Symbols used for connectivities are the same as 
reported in Figure III.1.5. The bundle of the region 175-193 of the best 30 DYANA structures was 
obtained by best fitting of the backbone (RMSD = 2.07 ± 0.61 Å). 
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PrP[180-195]. Figure III.1.7 shows the bar diagram of sequential and medium range 
NOE connectivities, as derived from the NOESY spectrum in TFE at 300 ms mixing 
time. Strong dNN(i,i+1) sequential and dαβ(i,i+3) medium range effects were typical of α-
helical structure. Figure III.1.7 also shows the superimposition of the region 182-191 
of the best thirty DYANA structures with a backbone RMSD of 0.45 ± 0.25 Å. 
 
 
 
 
 
 
 
Figure III.1.7 NOE effects and DYANA backbone fitting of PrP[180-195]. Connectivities were derived 
from NOESY spectra at 300 ms mixing time. Symbols used for connectivities are the same as 
reported in Figure III.1.5, but ▼ are used for torsion angles compatible with β-strand. The bundle of 
the region 182-191 of the best 30 DYANA structures was obtained by best fitting of the backbone 
(RMSD = 0.45 ± 0.25 Å). 
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Test of neurotoxicity 
 
Neurotoxicity of the α-helix 2 derived peptides was assayed on B104 neuroblastoma 
cells derived from rat central nervous system [144]. The cells were cultured in 
Dulbecco's modified Eagle's minimal essential medium and exposed to increasing 
peptide concentration. Percent of cell survival was assessed by comparison with 
untreated cultures used as control. The FC50 µM value, defined as the 50% fatal 
concentration, was estimated after 48 h exposure by testing peptides over a broad 
range of concentrations from 0 to 240 µM. FC50 values were determined by Hill plot 
analysis. In Table III.1.1 are summarized the FC50 values of the synthetic PrP 
fragments. 
 
 
 
                                   Table III.1.1 Neurotoxicity of α-helix 2 derived peptides 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peptide FC50 value (µM) 
PrP[173-195] 68 
PrP[173-195]D178N 12 
PrP[180-195] 11 
PrP[173-179] 430 
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III.2. Effect of salts and pH on PrP[180-195] and its H187A analogue 
 
 
As shown in Figure III.2.1(A), in the absence of any added salt, the shape of the 
circular dichroism (CD) spectra of peptides PrP[180-195] and PrP[180-195]H187A 
was suggestive of an unordered structure. Neither the addition of NaCl or NaClO4 nor 
the addition of small amounts of HCl or NaOH to adjust the pH caused any 
substantial modification. Spectra in sodium phosphate solution at pH 4.5, in which 
H2PO4− is the most populated anion, were also reminiscent of disordered 
conformation. By contrast, on addition of either sodium phosphate or sulfate at pH 
7.0, where bivalent HPO42− or SO42− anions are dominant, the spectrum of PrP[180–
195] was characterized by a pronounced negative maximum around 220 nm and a 
positive maximum around 200 nm, which are characteristic of β-sheet conformation 
(dashed lines in Figure III.2.1(B) and (C), respectively), whereas PrP[180-
195]H187A exhibited spectral features typical of the α-helix conformation, with a 
positive maximum around 195 nm and two negative maxima around 208 nm and 222 
nm (bold lines in Figure III.2.1(B) and (C), respectively). Finally, spectra of PrP[180-
195]H187A and PrP[180-195] were modified to those typical of the β-sheet and 
disordered structure, respectively, by acidifying the Na2SO4 solution to pH 4.5 
(Figure III.2.1(D)). 
 
 
 
Figure III.2.1 Effect of salts on circular dichroism (CD) spectra of PrP[180–195] and PrP[180-
195]H187A. 
(A) PrP[180-195]H187A dissolved in H2O (bold line), 100 mM NaCl (thin line), 100 mM NaClO4 (dotted 
line), and 30 mM NaH2PO4 (dashed line). CD spectra of PrP[180–195] under the same conditions (not 
shown) were superimposable on those of PrP[180-195]H187A. (B) PrP[180–195] (dashed line) and 
PrP[180-195]H187A (bold line) dissolved in 30 mM NaH2PO4/Na2HPO4 (pH 7.0). (C) PrP[180–195] 
(dashed line) and PrP[180-195]H187A (bold line) dissolved in 50 mM Na2SO4 (pH 7.0); the inset 
shows spectra of PrP[180-195]H187A as obtained by titration with Na2SO4 up to 50 mM (pH 7.0). (D) 
PrP[180–195] (dashed line) and PrP[180-195]H187A (bold line) dissolved in 50 mM Na2SO4 (pH 4.5). 
 
         
  
37 
            Table III.2.1 Effect of anions and pH on peptide conformation 
 
Medium C (mM) pH PrP[180-195] PrP[180-195]H187A 
water  4.5÷7.0 
Cl- 0÷100 4.5÷7.0 
ClO4- 0÷100 4.5÷7.0 
H2PO4- 0÷50 4.5 
 
disordered 
 
HPO42-/ H2PO4- 0÷50 7.0 β-strand α-helix 
SO42- 0÷50 7.0 β-strand α-helix 
SO42- 0÷50 4.5 disordered β-strand 
 
 
Table III.2.1 summarizes the above described CD effects. It is worth noting that the 
thermodynamic processing of these salt-induced structural changes show features 
typical of most structural transitions and are therefore suited to be treated by some 
thermodynamic model that hinges on the structuring effect of the anion activity. For 
example, the isodichroic point that can be noticed around 207 nm in the spectra of 
PrP[180-195]H187A at neutral pH (see inset of Figure III.2.1(C)) suggests a two-
state equilibrium between the unstructured peptide and the structured peptide, whose 
onset is accompanied by a sharp ellipticity change around 35–40 mM of salt (Figure 
III.2.2). 
 
 
Figure III.2.2 Effect of Na2SO4 on the ellipticity values of PrP[180-195]H187A at pH 7.0.  
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Notably, PrP[180-195]H187A in Na2SO4 at acidic pH assumes a β-sheet-like 
conformation, which is irreversibly destroyed by heating, with an apparent midpoint 
temperature (Tm) of about 47 °C. Concentration-dependent experiments performed 
in the 6–300 µM range show that the peptide behaviour on salt addition is more 
complex than that described above. As can be appreciated from Figure III.2.3, the 
observed ellipticity shows a hyperbolic trend in 50 mM Na2SO4, whereas it is 
expected to depend linearly on the peptide concentration, according to the Lambert 
Beer’s law. Such a deviation from linearity can be interpreted in terms of structural 
rearrangements that lead to self-association.  
 
 
 
 
Figure III.2.3 Peptide self-association at pH 7.0. () PrP[180-195] and () PrP[180-195]H187A. 
Concentration-dependent experiments were performed at 20 °C in 50 mM Na2SO4 maintaining the 
number of molecules in the optical path constant equimolecular condition. This was achieved by 
keeping the product of the protein concentration and optical path length constant. 
 
 
 
Furthermore, pseudo first order rate constants show an anomalous increase with the 
peptide concentration. This suggests a kinetic behaviour different from the first order 
expected for a simple conformational rearrangement involving monomers (Figure 
III.2.4). We infer therefore that both peptides self-associate. At least in the case of 
PrP[180-195]H187A it is apparent that this follows secondary structure 
rearrangements because it occurs in the presence of 50 mM Na2SO4, which is higher 
than the salt concentration at which structural modifications were observed (Figure 
III.2.2). In general, it cannot be excluded that structural reorganization and self-
association are to some extent concomitant.  
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Figure III.2.4 Time-dependence of PrP[180-195]H187A reorganization at pH 7.0. Experiments were 
performed at 20 °C on 2.5 µM (+), 5.0 µM (○), and 10 µM (●) peptide dissolved in 50 mM Na2SO4, 
monitoring the dichroic signal at 200 nm. Rate constants were calculated by best fitting to a pseudo 
first order kinetic equation, which gave 3.8 × 10−4, 4.5 × 10−4, and 11.0 × 10−4 s for 2.5, 5.0, and 10 × 
10−6 M peptide, respectively. 
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III.3. NMR and CD titration of PrP[173-195] and its D178N analogue with 
metal cations 
 
 
As shown in Figure III.3.1, the far UV CD spectrum of PrP[173-195] in TFE solution 
shows features typical of α-helical conformation. The small spectral alterations that 
can be noticed on metal (Zn(II) and Cu(II)) titration are likely caused by modification 
of the dielectric properties of the solvent subsequent to salt addition and do not 
suggest any specific binding interaction between the peptide and the metal cation. 
Figure III.3.2 depicts the amidic zone of the 1D spectra after Zn(II) addition. The 
addition of just one metal ion aliquot was sufficient to cause alteration of the 
imidazolic proton resonances. Concentration dependent peptide aggregation on 
further metal addition caused progressive broadening of all resonances, even 
causing them to disappear. Overall, this suggests non-specific metal-peptide 
interaction, a conclusion that is supported by the unchanged shape of CD spectra, 
where aggregation did not occur because of the lower peptide concentration.  
The lower intensity of the far UV CD spectrum of PrP[173-195]D178N, run in the 
same condition as that of hPrP[173-195] (Figure III.3.3), suggests that the mutant 
peptide is less helical as compared to the wild type peptide. However, the conclusion 
that no specific binding interaction with the metal cation can be detected still holds for 
this peptide. The amidic zone of 1D NMR spectra of PrP[173-195]D178N in the 
presence of various amounts of Zn(II) is reported in Figure III.3.4. The protonic 
resonances of the His side chains exhibit the same behaviour as that observed for 
the wild type peptide fragment, but the progressive broadening of side-chain 
resonances is less relevant. As already observed for PrP[173-195], these data are 
not suggestive of well defined ion-peptide complex formation. 
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Figure III.3.1 Far UV CD spectra of PrP[173-195] dissolved in TFE before and after addition of ZnCl2 
solution. A similar spectral behaviour was observed after titration with CuCl2 solution (spectra not 
shown). 
 
 
 
 
 
 
Figure III.3.2 1D NMR spectra of PrP[173-195] dissolved in TFEd2 before and after addition of ZnCl2 
solution. Labels 1, 2, 4 and 10 indicate the total volume (µL) of 0.5 M ZnCl2 solution added to 500 µL 
of 0.6 mM peptide solution, corresponding to Zn(II)/peptide molar ratios of 1.7, 3.3, 6.7 and 16.7, 
respectively. Imidazolic proton resonances of His residues in metal absence are marked by an 
asterisk. 
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Figure III.3.3 Far UV CD spectra of PrP[173-195]D178N dissolved in TFE before and after addition of 
ZnCl2 solution. A similar spectral behaviour was observed after titration with CuCl2 solution (spectra 
not shown). 
 
 
 
 
Figure III.3.4 1D NMR spectra of PrP[173-195]D178N dissolved in TFEd2 before and after addition of 
ZnCl2 solution. Labels 1, 2, 4 and 16 indicate the total volume (µL) of 0.5 M ZnCl2 solution added to 
500 µL of 1.0 mM peptide solution, corresponding to Zn(II)/peptide molar ratios of 1.0, 2.0, 4.0 and 
16.0, respectively. Imidazolic proton resonances of His residues in metal absence are marked by an 
asterisk. 
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III.4.  Integrated spectroscopical investigation and molecular dynamic 
simulation on tetracycline/α-helix 2 interaction 
 
 
CD investigation 
 
An extensive investigation of the interaction of PrP peptides with TC has been 
conducted in water by using fluorescence spectroscopy. To this aim, at the N-
terminus of each peptide was introduced fluorescein as fluorescent probe [145]. 
Before using any peptide in fluorescence studies, their conformation in water was 
evaluated by CD spectroscopy. In Figure III.4.1, an overlay of CD spectra of the 
fluoresceinated peptides Fluo-PrP[173-195], Fluo-PrP[180-195] and Fluo-βA[25-35] 
is reported. Unexpectedly, in water, the spectra of all peptides exhibited features 
typical of α-helix conformations, with a maximum at around 195 nm and two minima 
at around 208 and 222 nm. The CD spectrum of fluoresceinated Fluo-PrP[106-126], 
under the same conditions, shows that the polypeptide does not adopt canonical 
conformations; on the contrary, it is indicative of a random structure (Figure 
III.4.2(D)). Remarkably, the addition of increasing amounts of tetracycline (TC) to 
peptide solutions did not induce substantial structural changes (see Figure III.4.2), 
indicating that the effects produced by the antibiotic on peptide fluorescence 
emission (see later) were solely due to a direct interference with the fluorescein 
spectroscopic properties, and not to an alteration of peptide conformation. 
 
 
 
 
 
Figure III.4.1 CD spectra of the peptides Fluo-PrP[173-195] (red), Fluo-PrP[180-195] (magenta), and 
Fluo-βA[25-35] (blue) in water at 20°C. 
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Figure III.4.2 Effect of tetracycline addition on CD spectra of fluoresceinated peptides dissolved in 
H2O and in presence of 10 eq. of TC (green lines). (A) Fluo-PrP[173-195] (red line). (B) Fluo-PrP[180-
195] (magenta line). (C) Fluo-βA[ 25-35] (blue line). (D) Fluo-PrP[106-126] dissolved in H2O (yellow 
line). 
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Binding experiments 
 
The fluorescence emission spectra of peptide Fluo-PrP[173-195] in the presence of 
increasing amounts of TC are reported in Figure III.4.3(A) The fluorescence intensity 
definitely decreases as a function of increasing TC concentration and this feature is 
much more evident in Figure III.4.3(B), where intensity is plotted against the 
antibiotic concentration. The curve relative to Fluo-PrP[173-195] is superimposed to 
those of Fluo-PrP[180-195], Fluo-PrP[106-126], and Fluo-βA[25-35]. It is worth noting 
that, while curves of prion peptides corresponding to α-helix 2 show the hyperbolic 
trends expected by saturating dose-response effects, the Fluo-PrP[106-126] and the 
control Fluo-βA[25-35] exhibit a rather linear, nonsaturating dependence of 
fluorescence quenching on TC concentration, that is, typical for non-specific 
interactions. Non-linear regression analysis of curves relative to Fluo-PrP[173-195] 
and Fluo-PrP[180-195] provided an estimation of the apparent dissociation constants 
for the two peptide/TC complexes, which are 189±7 and 483±30 nM, respectively. 
Noteworthily, the dissociation constant of the shorter 180-195 fragment is about 2.5-
fold higher than that of the full length α-helix 2, pointing out that, though a strong 
interaction with the polycyclic molecule is yet maintained, a contribution to binding 
between α-helix 2 and TC must derive from either the N-terminal residues or from a 
superior conformational stability of the longer peptide. Under the explored 
concentration range (nM), no quenching effects have been detected with the 
fluoresceinated, conformationally random, N-terminal 106-126 fragment. The 
absence of any effect of TC on the spectral properties of Fluo-PrP[106-126] rules out 
the occurrence of non-specific interactions of the antibiotic with fluorescein and, at 
the same time, the lack of interaction of the structured Fluo-βA[25-35] excludes a 
preferential interaction of the antibiotic with unrelated helical structures.  
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Figure III.4.3(A) Fluorescence emission spectra of Fluo-PrP[173-195] in presence of increasing 
amounts of tetracycline. Curve intensities decrease upon TC addition, as indicated by the arrow (B) 
Effect of tetracycline addition on fluorescence quenching of Fluo-PrP[173-195] (●), Fluo-PrP[180-195] 
(○), Fluo-βA[25-35] (), and Fluo-PrP[106-126] () in water at 20°C.                                
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Docking calculations 
 
Automated docking calculations predict that both neutral TC (TCn) and zwitterionic 
TC (TCzw) exhibit a strong preference for the coordination to the C-terminal part of 
PrP[173-195]. Furthermore, it emerges that the three energetically most favorite 
orientations for TC docked to PrP[173-195] are the same for both TCzw and TCn 
(Table III.4.1 and Figure III.4.4). In both cases, the majority of the 100 lowest 
energy-docking structures belong to the same three clusters, which we label R1, R2 
and R3 according to their energy rank. This result can be easily explained by the 
inspection of the most stable docked structures, showing that the groups involved 
into zwitterionic equilibrium are indeed not directly involved into the interaction with 
PrP[173-195]. It must be noticed that TCn prefers R1 orientation (i.e., the lowest 
energy orientation), whereas the most populated cluster for TCzw is the R3. However, 
it is important to remind that cluster orientations have very similar stability. Almost all 
of the 100 most stable docked structures of TCzw belong to R1, R2, and R3, whereas, 
for TCn, structures involving the coordination to the N-terminal portion of PrP[173-
195] are also present. On the other hand, it is important to highlight that the average 
docking energy of these latter structures is significantly (more than 2 kcal/mol) lower 
than that of R1. Structures belonging to R1 are stabilized by hydrogen bonds 
involving both the polar side (carbonyl and hydroxyl groups) and the unique hydroxyl 
group of the apolar side of TC and residues Thr183, Gln186, His187, and Thr190 
(Figure III.4.5(a)). R3 complexes, instead, are characterized by hydrogen bonds 
between the polar side (carbonyl, hydroxyl, and amidic groups) of TC and the 
aminoacids Gln186, His187, Thr190, Thr191, and Lys194 (Figure III.4.5(b)). 
 
 
 
Table III.4.1 Docking Energy (in kcal/mol) and Percent Population on the 100 Lowest Energy-Docked 
Structures of the Three Preferred Orientations (see Figure III.4.4) for TCzw and TCn, according to 
AUTODOCK Calculations. 
Cluster type Percent Population 
     TCzn                    TCn 
Lowest Docked Energy 
    TCzn                           TCn 
Mean Docked Energy 
      TCzn                    TCn 
R1 
R2 
R3 
      12                    35 
       7                       6 
      70                     7 
    -7.43                    -7.42 
    -7.14                    -6.78 
    -6.62             -6.28 
    -7.22                    -7.05 
    -6.97                    -6.66 
   -6.62             -6.18 
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Figure III.4.4 Docked structures obtained by AutoDock calculations for (a) TCzw and (b) TCn. The 
three most stable clusters of docked structures are in color (red: R1, yellow: R2, green: R3). 
 
 
 
 
 
Figure III.4.5 Docked The structure with the lowest docking energy in clusters (a) R1 and (b) R3. 
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 Molecular dynamic simulations 
 
As a first step of our MD analysis, we have performed three different MD runs labeled 
MD1, MD2, and MD3) of the isolated PrP[173-195] fragment. On the balance, the 
fragment is predicted to adopt preferentially α-helix structure, in agreement with the 
indication of CD experiments. However, the analysis of the RMSD on Cα carbon 
atoms confirms the flexibility of this region, as shown by previous MD studies of PrP 
and thereof fragments [37, 146-148] and in agreement with the previously described 
conformational ambivalence of the isolated peptide [48]. The comparison among the 
different simulations indicates that the region more susceptible to loose helix 
structure comprises some residues in the middle of the fragment (residues 185-187) 
and, most of all, the C-terminal residues 193-195. As a matter of fact, two of the three 
MD simulations predict that significant conformational changes take place in the C-
terminal region (residues 189-194) during the second half of simulation, destructuring 
the initial helix conformation, and leading to the formation of a bend. The motion of 
Thr residues (190-193), especially that of side chains, critically influences the 
conformational behaviour of the C-terminal part of PrP[173-195]. When Thr residues 
(190-193) adopt an helix conformation, their side chains usually contribute to the 
stabilization of the helix, providing supplemental hydrogen bonds with the backbone. 
On the other hand, when Thr side chains of the C-terminal end freely fluctuate into 
the solvent, helix structures are much more unstable. Concerning the high flexibility 
of the C-terminal part of α-helix 2 and, in particular, the small tendency for Thr-rich 
regions to adopt helix conformations, our results agree with previous experimental 
and computational studies [14, 21, 37, 48].  
 
 PrP[173-195]/TCzw System 
Although with some different details, the three simulations, labeled MD1zw, MD2zw, 
and MD3zw, agree in predicting that TCzw strongly interacts with prion fragment. The 
analysis of the RMSD for the three simulations indicates that TC atoms rapidly reach 
the equilibrium, whereas PrP[173-195] fragment is more unstable. In two out of the 
three simulations, PrP[173-195] undergoes indeed significant conformational 
changes consisting in the loss of helical content at the C-terminus and in the middle 
of the fragment (around residues 183-185) (Figure III.4.6). However, it is important to 
highlight that, notwithstanding this distortion, PrP[173-195] still exhibits a 
predominant helical conformation, in agreement with CD experiments. In all the 
simulations, TCzw interacts strongly with the prion fragment, being characterized by at 
least two stable hydrogen bonds between the polar side of TC and the C-terminal 
part of PrP[173-195]. In detail, MD1zw and MD3zw show a similar behaviour, 
exhibiting two stable intermolecular hydrogen bonds. The first one involves Thr190 
and the polar side of TC, while the second one is formed by Ile182 (MD3zw) or 
Thr184 (MD1zw), respectively (Figure III.4.6(a) and (c)). In MD2zw, there is instead 
alternation between adducts stabilized by two and three hydrogen bonds, namely, 
between the polar side of TC and Thr191 and Lys194 and/or Gly195 (Figure 
III.4.6(b)).  
 
 PrP[173-195]/TCn System 
On the balance, also when interacting with TCn, helix conformation of PrP[173-195] is 
maintained. However, as found also in the absence of TC, the C-terminal region is 
very flexible. Depending on the simulation, between 2 and 6 C-terminal residues are 
indeed predicted to loose helix conformation (Figure III.4.7). Confirming the results 
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obtained on TCzw, MD simulations, labeled MD1n, MD2n, and MD3n, predict the 
formation of a stable interaction between TCn and PrP [173-195], stabilized by at 
least two persistent hydrogen bonds (Figure III.4.7). 
 
 
 
 
Figure III.4.6 Representative frames extracted during the MD1zw (a), MD2zw (b), and MD3zw (c) 
molecular dynamic simulations. 
 
 
 
 
 
Figure III.4.7 Representative frames extracted during the MD1n (a), MD2n (b) and MD3n (c) 
molecular dynamic simulations. 
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III.5. Fluorimetric analysis of α-helix 2–binding synthetic peptide 
constructs 
 
 
The structure of the complex Fab-ovPrP shows that the epitope of the antibody 
consists mostly of PrP residues 188–199 (C-terminal part of α-helix 2 and N-terminal 
part of the α-helix 2/α-helix 3 loop) [127]. 
As shown in Figure III.5.1, we have identified the Fab[30-35] and Fab[46-53] 
fragments (TNYGMN and RLIYLVSR, respectively), which are able to form hydrogen 
bonds with the α-helix 2 C-terminal end in the Fab-ovPrP X-ray structure and 
designed peptide constructs putatively suitable to model the ovPrP-Fab interaction.  
 
 
 
 
 
 
Figure III.5.1 (Left) Overview of the complex. (Right) Close-up view of the boxed region of the 
complex. For clarity, only atoms that establish an intermolecular hydrogen bond (dashed lines) are 
represented in the ‘stick’ format.  
 
 
 
 
 
These peptide constructs, henceforth identified as JMV, were obtained linking the 
two identified peptide fragments by spacers of different size, rigidity and chemical 
nature; their general scheme of synthesis on SynPhase Lanterns is reported in 
Figure III.5.2.  
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Figure III.5.2 Scheme of synthesis on SynPhase Lanterns of JMV peptide costructs. 
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Subsequently, in order to investigate the interaction between α-helix 2 and JMV 
compounds, we have recorded the emission spectra of fluorescein-modified PrP[173-
195] in aqueous solution in presence of increasing amounts of JMV compounds. The 
fluorescence emission spectra of Fluo-PrP[173-195] in presence of increasing 
amount of JMV3391 are representatively reported in Figure III.5.3(A). The 
fluorescence intensity decreases following JMV addition was appreciated by plotting 
modification of the emission intensity at 518 nm versus JMV concentration. All 
titration curves show the hyperbolic trend typical of saturating dose-response effects 
(Figure III.5.3(B)). Fluorescence intensities were then used to evaluate the fractions 
of Fluo-PrP[173-195] bound to each JMV construct and calculate the apparent 
dissociation constants (KD’) of the corresponding complexes according to 1:1 binding 
interaction (Table III.5.1).  
 
 
Figure III.5.3(A) Fluorescence emission spectra of Fluo-PrP[173-195] in presence of increasing 
amounts of JMV3391, curve intensities decrease upon JMV3391 addition, as indicated by the arrow. 
(B) Effect of JMV addition on fluorescence quenching of Fluo-PrP[173-195]. 
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   Table III.5.1 JMV compounds: apparent dissociation constants and corresponding structures and    
   symbols. 
 
 
Finally, in order to analyze the potential correlation between the KD’ value and the 
conformation, a CD analysis of the JMV compounds was performed in aqueous 
solution. As shown in Figure III.5.4, the shape of the circular dichroism (CD) spectra 
of all JMV peptide constructs in water at pH 7.0 was suggestive of an unordered 
structure. 
 
 
Figure III.5.4 CD spectra of JMV compounds in water at pH 7.0. 
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IV. DISCUSSION 
 
IV.1. Comparative CD, NMR and cellular toxicity study on PrP[173-195], its 
D178N analogue and the shorter PrP[180-195] segment 
 
 
We have performed comparative CD, NMR and cellular toxicity studies on the 
synthetic peptides PrP[173-195], PrP[173-195]D178N and PrP[180-195]. The first 
two peptides, corresponding to the full length α-helix 2 region, represent the wild type 
sequence and its D178N mutant, respectively. The shorter peptide includes the 
threonine-rich region and is therefore characterized by strong β-sheet forming 
propensity [133, 149, 150]. Furthermore, its structure is devoid of effects linked to the 
reactivity of the thiol moiety. Finally, it can be considered the peptide of maximal 
length that exhibits a regular structure different from the α-helix. This conclusion 
stems from the finding that the CD spectra of peptides derived from the N-terminal 
and the C-terminal part of the full length α-helix 2 (PrP[173-179] and PrP[180-195], 
respectively) are those typical of random and β-type organization, respectively 
(Figure III.1.2 and Figure III.1.1). Thus, it seems reasonable to infer that the 
occurrence of disordered structure in the full length α-helix 2 peptides is associated 
with the N-terminal segment. As a matter of fact, CD spectra of PrP[173-195] and 
PrP[173-195]D178N, which both include the 173-179 segment, do not show the β-
type peculiarities exhibited by PrP[180-195]. SDS titration of the D178N mutant goes 
to completion in a range of detergent concentration much narrower than that 
observed for the wild type peptide (see Figure III.1.3). Probably, the absence of the 
negative charge carried by the Asp178 side-chain permits stronger electrostatic 
interaction between SDS and the protonated His177 side-chain. Moreover, the higher 
β-inducing propensity of Asn may also contribute to favour reorganization of PrP[173-
195]D178N into a β-type conformation. Overall, this suggests that the Asn side-chain 
renders the mutant peptide more prone to form β-structure. In agreement with that, 
the TFE-induced recovery of α-helical conformation is larger for the wild type peptide 
compared to the D178N mutant (see Figure III.1.4). 
In addition, the fact that PrP[180-195] is able to assume β-arrangement at neutral pH 
even without SDS and that conformation doesn’t dramatically change even in 
presence of TFE, suggests that the 180-195 parental region in PrPC strongly 
contributes to the chameleon conformational behaviour of the segment 
corresponding to the full-length α-helix 2 [48] and could play a role in determining 
structural rearrangements of the entire PrPC-globular domain.  
Our CD spectra show that these α-helix 2 derived peptides do not possess the same 
α-helical conformation as that observed in the cellular prion protein. It is known that 
the lack of mutual interactions has dramatic effects on the integrity of the whole 
helical domain of the prion protein, and the stability of one single helical region 
strongly suffers from ablation of the other helical segments as well as of the 
disulphide bridge. However, native-like conditions can be to some extent restored 
choosing a medium that may help extract useful information using the peptide 
fragment approach. Thus, we have used TFE as the most suitable environment to 
investigate structural similarities between these synthetic peptides. 
As a matter of fact, in NMR spectra, both PrP[173-195] and PrP[180-195] were found 
to be helices, whereas the PrP[173-195]D178N mutant was not even able to retain a 
fully helical arrangement in an α-inducing environment. 
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The major NMR result is that the conformation of the wild type peptide is significantly 
affected by replacing the negatively charged Asp178 with a neutral Asn residue. In 
the mutant peptide, increased conformational freedom characterizes all residues 
downstream Gln188, which ultimately causes unwinding and bending of the wild type 
fully helical structure. As a consequence, structural rearrangement leads to the 
formation of two short helices separated by a kink centred on Lys185 and Gln186. In 
this bent structure, His177 and His187 approach to each other as compared to the 
parent helical peptide, forming two major conformational families, characterized by 
proximal and distal imidazole rings, respectively. Moreover, the network of stabilizing 
H-bonds mainly involves the interaction between Asn174 and Thr188 (head-to-tail 
type) and between Asn181 and His187 or Gln186 (core type) (Figure IV.1.1). In 
conclusion, we argue that the negative charge of Asp178 plays a key role in forcing 
the entire 173-195 fragment to assume a full helical conformation.  
Notably, the shorter 180-195 fragment still retains an almost fully helical structure, 
whether or not it is embedded in the 173-195 sequence, suggesting that helix 
unwinding in the region 180-187 is provoked by the D178N substitution. Indeed, 
though the sequence of the shorter peptide includes residues involved in the bending 
of the D178N analogue (Lys185 and Gln186), it does not show any kink in its 
structure, nor does the wild type peptide. This confirms that the D178N mutation 
destabilizes the region in which it is located, thus causing not only the unwinding of 
the wild type fully helical structure, but also its bending.  
 
 
 
 
 
 
 
 
Figure IV.1.1 Stereo view of the backbone structure of PrP[173-195]D178N. Clusters identify two 
major conformational families, with proximal (top) and distal (bottom) histidine imidazolic rings. 
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Interestingly, comparing the FC50 value of Table III.1.1 it is evident that the PrP[180-
195] peptide and the complementary PrP[173-179] fragment possess the lowest and 
the highest FC50, respectively, whereas the peptide derived from the full α-helix 2 
(PrP[173-195]) displays an FC50 slightly higher than that of PrP[180-195]. This 
suggests that the intrinsic toxicity of PrP[173-195] can be totally ascribed to the 
segment 180-195. Furthermore, the peptide bearing the D178N mutation associated 
to the CJD displays a toxicity higher than that of the wild type peptide. This value is 
probably related to the structural destabilization caused by the Asp178 Asn 
replacement.  
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IV.2. Effect of salts and pH on PrP[180-195] and its H187A analogue 
 
 
Environmental conditions, like pH, salts, and presence of nucleic acids or 
glycosaminoglycans, seem to affect the structural stability of prion proteins to a much 
larger extent than other proteins [151-158]. It was suggested that this unusual 
behaviour could be ascribed to the ability of PrPC N-terminal region to interact with 
anions, which leads to destabilization of the prion core structure [155]. Also, in an 
extensive analysis on the interaction of anti-prion compounds and amyloid-binding 
dyes with a carboxy-terminal domain of prion protein, it has been found that 
sulfonates, like Congo red and phthalocyanine tetrasulfonate, bind with high affinity 
[159]. We have shown that the conformational properties of two PrPC α-helix 2-
derived analogues, PrP[180–195] and PrP[180-195]H187A, are affected by anion 
identity. Such large differences in the CD spectra of both peptides with anion identity 
can be rationalized via the ion charge density dependence that is typical of 
Hofmeister effects [134, 135] (Figure IV.2.1).  
 
 
 
Figure IV.2.1 Weakly hydrated chaotropic anions (top) maximize the solvent accessible surface area 
and favor the unordered structure in both PrP[180–195] and PrP[180-195]H187A. Strongly hydrated 
kosmotropic anions (bottom) make bulk water a poorer solvent and cause PrP[180-195]H187A and 
PrP[180–195] to fold to α-helix and β-structure, respectively, to minimize their solvent accessible 
surface area. 
 
Anions like Cl−, ClO4−, and H2PO4− are weakly hydrated because of their low charge 
density, and their interaction with water molecules is weaker than that of water with 
itself. This causes them to behave as water structure breakers (chaotropes), which 
make the bulk solution a better solvent. As a consequence, both PrP[180–195] and 
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PrP[180-195]H187A maximize their solvent accessible surface area, favoring the 
formation of the unstructured conformation. On the other hand, multiply charged ions, 
like SO42− and HPO42−, exhibit stronger interactions with water molecules than water 
with itself because of their high charge density. These ions are water structure 
makers (kosmotropes) and make the bulk solution a poorer solvent. Thus, they 
encourage PrP[180–195] and PrP[180-195]H187A to minimize their solvent 
accessible surface area and assume β-sheet-like and α-helix-like conformations, 
respectively. It is likely that the compactness of these structures predisposes both 
peptides to self-association (Figure III.2.3), which may be a preliminary step toward 
fibril formation. This is also suggested by preliminary heat irreversible denaturation 
experiments on PrP[180-195]H187A, which assumes a β-sheet-like conformation 
when dissolved in Na2SO4 at acidic pH. The different conformational behaviour of the 
wild type peptide as compared to the mutant peptide in the presence of kosmotropic 
anions at neutral pH is likely caused by the His side chain, which displays an α-
inducing ability lower than the Ala side chain. Nevertheless, in the prion protein, the 
segment containing the His187 residue is still able to retain an α-helical conformation 
owing to tertiary interactions [48]. Furthermore, in acidic solution, the His protonation 
and increased proton exchange [157] could play a role in causing PrP[180–195] and 
PrP[180-195]H187A to assume disordered structure and β-conformation, 
respectively. Also, our results confirm the chameleon like character of the helix 2 
domain [48], suggesting that preferential binding with naturally occurring anions, 
rather than non specific interactions, such as ionic strength-dependent interactions, 
plays an important role in prion protein misfolding and amyloid fibril growth. 
Understanding ion-specific effects is a central theme of biology. Unfortunately, the 
complication of ‘ion confounding’ is extremely common in all disciplines concerned 
with ion-based research because ions are generally manipulated through the use of 
salts. It occurs because changing the concentration of a single cation or anion using 
a single salt results in a simultaneous change of the associated co-ion, which causes 
the main effect associated with that ion to be confounded with the effects caused by 
changing the concentration of the co-ion [160]. It is therefore worth stressing that, 
even in studies on prion and derived peptides, anion-bound effects may overlap the 
largely explored cation-bound effects. Unfortunately, experiments are not always 
designed so that the species that cause the modification can be unequivocally 
perceived. In conclusion, we highlight that the sensitivity of our peptides, as well as 
the entire prion proteins [47, 52, 53, 78] or other amyloidogenic systems [161], to 
environmental modifications suggests that the complication of anion involvement 
cannot be neglected anymore, either in investigating metal effects on peptide 
conformation [47, 52, 53, 78, 161] or in checking the inhibition of amyloid formation 
by unusual agents [162, 163]. 
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IV.3. NMR and CD titration of PrP[173-195] and its D178N analogue with 
metal cations 
 
 
We have performed CD and NMR titration of the synthetic peptides PrP[173-195] and 
PrP[173-195]D178N with metal cations. As can be judged from far UV CD spectra 
(Figure III.3.1 and Figure III.3.3), the two negative bands at 222 and 208 nm, and a 
positive band at 192 nm indicate that both peptides exhibit α-helical arrangement. 
However, the lower intensity that characterizes the spectrum of the mutant peptide 
suggests some rearrangement as compared to the single helical structure exhibited 
by the wild type peptide.  
For both peptides, addition of increasing metal cation aliquots did not perturb NMR 
spectra in any specific way. The chemical shifts of all resonances did not vary, as it 
could be expected in case of metal-peptide complex formation, and the overall effect 
was a progressive generalized broadening of all relevant resonances. In fact, 
addition of higher and higher metal aliquots caused irreversible aggregation, which 
always lies in wait when the peptide concentration is very high, possibly owing to 
ionic strength increase and/or to water addition on metal cation titration. However, 
that the interaction of the metal with the peptide backbone is non-specific was 
confirmed by the unaltered appearance of CD spectra after metal addition, where 
aggregation did not occur thanks to the lower peptide concentration. These analyses 
were performed in neat TFE in conformity to the NMR experimental conditions of the 
III.1. Paragraph, but further experiments in mixed water/TFE solvent suggested that 
water-induced effects largely dominate structural rearrangements, rendering metal-
induced modifications, if any, hard to discriminate. Among studies that have been 
carried out on metal interaction with peptides derived from the PrP C-terminus, it is 
worth mentioning that recently Brown and co-authors [47] have characterized the 
formation of different Cu2+ complexes in blocked and free C- and N-termini analogues 
of the peptide fragment 180-193 (VNITKQHTVTTTT), which almost entirely 
encompasses the PrPC α-helix 2. They suggested that the binding site of copper(II) in 
the structured region of the protein is located on the His187 residue, and that the 
anchoring imidazole residue drives the metal coordination environment towards a 
common binding motif in different regions of the prion protein. Other studies [4] 
showed that the PrP[178-193] peptide has both structural and bioactive properties in 
common with the amyloidogenic Alzheimer's disease βA[25-35] peptide and that the 
second putative helical region of PrP could be involved in modulation of Cu(II)-
mediated toxicity in neurons during prion disease. However, our results suggest that 
the interaction of metal cations with peptide fragments derived from the C-terminal 
globular domain could be affected by experimental ambiguity caused by the fact that 
the structural organization of these peptides is different from that assumed in PrPC. 
We believe that it is crucial to take this aspect into account when designing 
experiments aimed at investigating peptide-metal cation interaction. Furthermore, in 
the peptide fragment approach, it is unlikely that aqueous buffer is the most suitable 
environment to analyze metal interaction with peptide fragments, whose parent 
segments in the native protein experience different environmental conditions. We 
have shown that the use of the α-helix-inducer TFE to force peptides into a 
conformation close to the helical one that has been found in PrPC may lead to 
conclusions different from those that can be obtained studying metal cation 
interaction with peptides in buffer solution. To embed our results in the body of data 
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on PrP structure and function, it is worth considering that the three-dimensional 
architecture of PrPC consists of an unstructured leading tail encompassing residues 
23-125 and a C-terminus globular domain, in which residues 126-231 are organized 
in three α-helices and a two-stranded β-sheet [14]. Although it is currently believed 
that the major structural modifications involved in PrP protein misfolding are located 
in the unstructured N-terminal region, the present results seem to provide further 
support to evidence accumulated in the literature that the two prion domains play a 
different role in the prion conversion, stressing that the N-terminal domain is likely the 
natural target of metal binding [53, 54]. 
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IV.4.  Integrated spectroscopical investigation and molecular dynamic 
simulation on tetracycline/α-helix 2 interaction 
 
 
An integrated approach comprising fluorescence spectroscopy and calculations has 
been utilized to investigate the interaction between the α-helix 2 of prion protein and 
the antibiotic TC. To evaluate the meaningfulness of our results for understanding the 
interaction between TC and the entire structured core of human prion protein, a 
preliminary investigation of the conformational properties of isolated PrP[173-195] 
and PrP[180-195] peptides has been undertaken. In this respect, experimental and 
computational results are globally comforting and converge toward the indication that 
the general behaviour of the peptides is quite similar to that of α-helix 2 within the 
PrP protein. As a matter of fact, both Fluo-PrP[173-195] and Fluo-PrP[180-195] 
synthetic peptides tend to adopt a prevailingly helical structure, either when isolated 
and in the presence of TC. Consistently, MD simulations, performed with both the 
173-195 fragment alone and in the presence of TC, strongly suggest that the N-
terminal half of the fragment, though flexible, shows a clear-cut preference for helical 
conformations. On the other hand, the C-terminal end, encompassing residues 189-
194, exhibits a much higher mobility. This result agrees with reported observations 
about the behaviour of α-helix 2 and further confirms the conclusions reached by 
Dima and Thirumalai [147] who have shown that the instability of α-helix 2  is 
independent of the protein intact structure. A further interesting feature emerged from 
the MD simulation on the isolated peptides regarding a modulation of the 
conformational behaviour of the C-terminal part of α-helix 2 exerted by the threonine 
side chains. Indeed, they can switch from a α-helix-stabilizing backbone interaction 
towards a solvent exposed conformation similar to that involved in the β-strand in the 
crystal dimer [21]. This outcome substantiates previous results based on X-ray [21] 
and NMR [14] studies that have demonstrated a high mobility of the Thr-rich region 
190-193 region.  
For what concerns the interaction with TC, experiments and calculations agree in 
predicting that TC has a strong affinity towards α-helix 2. As a matter of facts, 
fluorescence experiments indicates that the association constants of TC with Fluo-
PrP[173-195] and Fluo-PrP[180-195] is in the nM range, whereas the Fluo-βA[25-35], 
though in a helical conformation, is unable to bind to the antibiotic in the explored 
concentration range. Anyhow, the experimental apparent association constant is 
smaller for the longer peptide, suggesting either a ‘direct’ interaction of those 
residues with TC and/or a smaller stability of the helix conformation in the shorter 
peptide. Furthermore, docking calculations and MD simulations do not predict that 
the 173-180 residues are significantly involved in TC interaction, whereas the C-
terminal end, encompassing aminoacids 183-195, shows a strong affinity. 
Interestingly, MD simulations also suggest that the interaction between TC and prion 
peptides does not dramatically depend on the conformation adopted by the 
fragments, as stable hydrogen bonds can be formed with TC both in helix-like and in 
more extended conformations. In the C-terminal part of α-helix 2, there is indeed a 
hydrophilic patch in which several residue side chains potentially interacting with TC 
are gathered: Thr183, Gln186, His187, Thr190-193, Lys194. As a consequence, we 
can expect that, independently of the peptide conformation, two or three side chains 
can arrange in such a way to allow a strong interaction with the TC polar groups. 
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According to this hypothesis, the effect of TC on prion protein could be twofold: on 
one hand, a stabilization of the fluctuating helix conformation of the C-terminal part of 
α-helix 2 that prevents potentially dangerous transition to more extended 
conformations can be hypothesized. On the other hand, TC could interact with the 
peptide in the extended conformation, thus preventing protein association and the 
further aggregation into fibrils. Noticeably, among the C-terminal aminoacids of α-
helix 2, threonine residues are significantly involved in the interaction with TC. 
Although previous studies by NMR have prompted a direct interaction of TC with the 
106-126 peptide [113], these indications are not supported by our fluorescence 
experiments. In this regard, we suppose that affinity for this unstructured domain is 
much less intense being indeed detected at concentrations higher than those 
explorable by fluorescence (high micromolar range). 
Besides the similarities between the conformational behaviour of the isolated 
fragments and that of α-helix 2 within the full length protein, a further distinctive 
element suggests that our findings can provide useful hints also on the interaction of 
TC with the entire protein. The region of the peptide PrP[173-195] involved into 
interaction with TC corresponds to a solvent-exposed region also in the entire protein 
PrP[125-228]. This tract can thus potentially interact with TC without significant 
conformational rearrangements. This conclusion is confirmed by a preliminary 
docking study carried out on both PrP[125-228] and on a model PrP[117-228] (with 
the addition of the 117-125 tail according to the X-ray human structure) with TCn 
molecule. These results indicate that there is a strongly-preferred cleft for TC binding 
individuated by the region between the C-terminal end of α-helix 1 and the C-terminal 
end of α-helix 2. 
We believe that the hypothesis on the TC binding suggested by our results has 
interesting, though indirect, implications for what concerns the conformational 
transition of the prion protein to the pathological isoform. As a matter of fact, 
experimental evidence indicates that TC interacts with PrPSc and slows down the 
onset of the illness [113, 164] and we have shown that the C-terminal region of α-
helix 2, also in consideration of the high affinity, is one of the best candidate to be 
involved in the interaction with TC. These results, confirmed by preliminary docking 
calculations of TC and the entire PrP protein, could open interesting perspectives for 
the diagnosis and the use of TC derivatives for inactivating pathogenic form of PrP. 
From a complementary point of view, the experimental results concerning the 
capability of TC in retarding the onset of the illness, together with our observations, 
constitute an additional and significant, though indirect, hint for the involvement of the 
C-terminal part of α-helix 2 (especially, the threonine cluster) in the conformational 
transition, leading to the formation of the pathogenic form of PrP or at least in the 
formation of the recognition surfaces that hold together the misfolded monomers.  
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IV.5. Fluorimetric analysis of α-helix 2–binding synthetic peptide 
constructs 
 
 
We have reported the spectroscopic studies on the interaction between the α-helix 2 
derived peptide and peptide costructs putatively suitable to model the ovPrP-Fab 
interaction [127]. 
As can be judged from KD’ values listed in Table III.5.1, these preliminary 
experiments suggest that all Fab peptide constructs strongly interact with the α-helix 
2-derived fragment, particularly the JMV 3391, which shows the highest affinity (KD’ = 
2.3 nM). At the present these results have several different explanations. First, all of 
the spacers could be able to correctly orientate the peptide arms of the constructs. 
This hypothesis is supported by CD evidence that the JMV compounds assume an 
unordered structure and therefore no preferential organization has been identified for 
any of them. Second, only one peptide arm could be capable of interacting with the 
173-195 peptide, and any affinity enhancement could be due to assembling of the 
second peptide arm through the spacers. Last, affinity could be poorly correlated to 
size, rigidity and/or chemical nature of the spacer and reasonably ascribed to 
sequence-specific features of the interaction between the 173-195 fragment and the 
JMV peptide constructs. Further studies are necessary to clarify structural details of 
this interaction. Whether or not spacer linking of the two Fab peptide sequences is 
advantageous could be clarified by fluorescence titration of the α-helix 2 derived 
peptide with the single Fab[30-35] or Fab[46-53] fragment. In addition, NMR 
experiments could be planned to identify residues involved in α-helix 2-JMV 
compound interaction. 
Finally, experiments using more significant prion protein fragments could open 
interesting perspectives for the diagnostic or therapeutic use of these constructs in 
PrP-associated diseases. 
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V. CONCLUSIONS 
 
 
Prion diseases are a group of transmissible neurodegenerative disorders that 
enclose scrapie in sheep, spongiform encephalopathy in cattle (BSE), and 
Creutzfeldt–Jakob disease, fatal insomnia and Gerstmann–Sträussler–Scheinker 
disease in humans.  
The pathogenic mechanism underlying these diseases is a conformational 
conversion of the cellular prion protein (PrPC) into disease-specific species (PrPSc) 
that possess abnormal physicochemical properties, such as insolubility and protease 
resistance, and accumulate in the brain in the form of amorphous aggregates and 
amyloid fibrils [8]. 
Despite a large number of studies on PrPC, possible causes of its pathogenic 
conversion and its role in cellular function still remain unclear. Moreover, the highly 
aggregated state of the abnormal form has hampered the elucidation of the PrPSc 
structure at the atomic level. 
Importance attached to prion protein studies has remarkably increased following the 
BSE epidemic and appearance of a new variant of Creutzfeldt-Jakob disease that 
seems to be causally linked to it [165-167]. Although the number of CJD cases 
observed so far is limited, a future outbreak of this disease cannot be excluded. 
Moreover, given that general features of prion diseases are common to other amyloid 
disorders [2], the prion protein could be used as a model to provide the bases for a 
comprehensive evaluation of the general protein misfolding mechanism. 
It is therefore evident that a conformation based approach to the study of PrP can 
give useful hints both on the region/residues potentially important for the PrPC→PrPSc 
conversion and on the identification or development of anti-prion compounds. 
Following the thread of these arguments we have investigated the conformational 
properties of the PrP[173-195] peptide, corresponding to hPrP α-helix 2, and its 
affinity towards potential PrP-binding compounds. The interest in the study of α-helix 
2 comes from evidence that this segment possesses chameleon conformational 
behaviour [48], gathers several disease-promoting point mutations, and can be 
strongly fibrillogenic and toxic to neuronal cells [4], suggesting its involvement in the 
protein aggregation process and in the toxicity associated to the scrapie variant. 
Overall, all our data on the conformational landscape of α-helix 2 strongly suggest 
that the role played by the α-helix 2 domain is not to be considered neutral in the 
misfolding mechanism of the PrPC to the scrapie isoform. 
In particular, the CD and NMR analysis on the synthetic α-helix 2 derived peptides 
has shown that the 173-195 segment is characterized by unusually low α-helical 
content and high β-sheet propensities, in spite of the fact that this segment retains a 
helical conformation in the whole protein. This behaviour could be ascribed to the 
180-195 fragment which includes the threonine-rich region and is able to assume a 
β-arrangement at neutral pH even without SDS or in presence of TFE. 
Moreover, a single amino acid replacement in the α-helix 2 significantly affects the 
organization of the 173-195 peptide, enhancing the propension of this region for β-
conformation and facilitating structural rearrangements. As a matter of fact, in the 
CJD-associated D178N mutant peptide, the substitution of a neutral Asn for an Asp 
residue weakens the helical arrangement of the 173-195 segment in TFE. In addition, 
the PrP[173-195]D178N peptide shows a higher β-type propensity in SDS compared 
to that exhibited by the wild type peptide in the same condition. Furthermore, 
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neurotoxicity assays have shown that the PrP[180-195] and PrP[173-195]D178N 
peptides display a toxicity higher than that of the wild type peptide, suggesting a 
linkage between β-conformation propensity and toxicity. 
On the other side, enviromental conditions, such as pH and salts, can affect the 
conformational behaviour of the α-helix 2 domain. This confirms the chameleon-like 
character of this PrP fragment [48], suggesting that preferential binding with naturally 
occurring anions and pH changes play an important role in prion protein misfolding 
and amyloid fibril growth. 
NMR and CD titrations with metal cations have shown that no specific interaction of 
Zn2+ or Cu2+ with α-helix 2 derived peptides occurs, providing further support to 
evidence accumulated in the literature that PrP N- and C-termini domains play a 
different role in the prion conversion and stressing that the N-terminal domain is likely 
the natural target of metal binding [53, 54].  
Its intriguing structural properties make the α-helix 2 domain a primary target for 
therapeutic strategies and a suitable model to investigate rational structure-based 
drug design of compounds able to block or prevent prion diseases. 
For what concerns the interaction with TC, experiments and calculations agree in 
predicting that TC has a strong affinity towards the α-helix 2 and that interaction 
mainly involves its C-terminal half, previously shown to be conformationally 
ambivalent [48] and suggested as a starting point of oligomerization [14].  
TC could therefore stabilize the fluctuating conformation of the C-terminal part of the 
α-helix 2 preventing its structural transition and aggregation. 
Moreover, we believe that the results on TC binding have interesting, though indirect, 
implications for the PrPC→PrPSc conformational transition. Although previous NMR 
studies in the mM concentration range have demonstrated direct interaction of TC 
with the PrP[106-126] peptide [113], our fluorescence experiments in the sub-
micromolar range suggest instead that the TC affinity toward this unstructured 
fragment is much lower than that displayed toward the PrP[173-195] peptide. These 
results, confirmed by preliminary docking calculations on the interaction between TC 
and the whole PrP, indicate that the α-helix 2 C-terminal part is one of the best 
candidates to be involved in the binding to TC. Therefore, the previously described 
ability of TC to reduce, block and revert effects produced by pathological forms of 
hPrP [113, 164] could be predominantly ascribed to the interaction of TC with the α-
helix 2. These results can have important implications for the use of TC derivatives 
for inactivating pathogenic forms of PrP and constitute an additional and significant 
hint for the involvement of the C-terminal part of the α-helix 2 in the PrPC→PrPSc 
conversion.  
In order to shed further light on the importance of the α-helix 2 domain as target for 
therapeutic and diagnostic approaches in prion diseases, we have designed and 
synthesized peptide costructs able to interact with the 173-195 peptide. Although this 
aspect needs further investigation, our results open interesting perspectives for the 
use of these constructs as therapeutic and diagnostic tools in PrP-associated 
misfolding. 
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VI. EXPERIMENTAL SECTION 
 
VI.1. Materials 
 
 
All solvents were peptide synthesis grade. HPLC chemicals and other organic 
reagents were purchased from Sigma-Aldrich (Milan, Italy). N-αFmoc-protected 
aminoacids, the activating agents and the resin were purchased from Novabiochem 
(Läufelfingen, CH). SDS and TFE were obtained from Sigma-Aldrich (Milano, Italia) 
and Romil LTD (Dublin, Ireland), respectively. Dulbecco’s modified Eagle’s medium 
was from Euroclone Life Science (Milan, Italy). MTT was from SIGMA-Aldrich (St. 
Louis, MO, USA). Lanterns, cogs and spindles were purchased from Mimotopes.  
 
 
 
VI.2. Solid Phase Peptide Synthesis  
 
 
Peptide of Table II.1  
 
The peptides reported in Table II.1 were synthesized by Fmoc standard chemistry 
protocol on Rink-amide 4-methylbenzhydrylamine (MBHA) resins 0,63 mmol/g. The 
Fmoc-amino acid side chain were selected as follows: tBu (Asp, Glu, Ser, Thr, Tyr), 
Boc (Lys), Pbf (Arg), Trt (Cys, Asn, Gln, His). Generally, the peptide chains were 
assembled by the sequential coupling of activated N-αFmoc-protected aminoacids (3 
eq) in DMF in the presence of HBTU (3 eq) and DIEA (6 eq) with a reaction time of 1 
h at room temperature. The resins were than washed with DMF (x 3), MeOH (x 1) 
and DCM (x 3). The completeness of each coupling was verified by the Kaiser test 
[168]. N-αFmoc deprotection was carried out by treatment with piperidine (20% v/v in 
DMF) for 30 min followed by washing with DMF (x 3), MeOH (x 1) and DCM (x 3). If 
necessary, the coupling and deprotection cycles were repeated. After the assembling 
of peptides reported in Table II.1(A), acetylation was carried out by treatment with 
acetic anhydride (50% v/v in DCM). At the N-terminus of peptides reported in Table 
II.1(B), a β-Alanine was linked and, after Fmoc removal, fluorescein was added using 
fluorescein isothiocyanate (2 eq) and DIEA (2 eq) for 2 h at room temperature. The β-
Alanine residue was introduced as spacer and to avoid fluorescein elimination by the 
Edman degradation mechanism. 
The peptides were then cleaved from the resin with TFA in the presence of TIS and 
distilled water (90 : 5 : 5, v/v/v) for 2 h at room temperature, concentrated in vacuo, 
and precipitated with diethyl ether at 0°C followed by centrifugation at 3000 rpm for 5 
min (x3). The resultant peptides were dissolved or suspended in water/acetonitrile 
(1:1, v/v) mixture and lyophilized.  
In Figure VI.2.1 and VI.2.2 are representatively reported the LC-MS profiles of 
PrP[180-195] and Fluo-PrP[180-195]. In Table VI.2.1 are listed, per peptide: the 
molecular formula and the exact mass, the retention time (tR) and the masses 
(derived from the LC-MS analyses) and the yield of peptide after purification.   
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Figure VI.2.1 LC-MS profile of PrP[180-195]. 
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Figure VI.2.2 LC-MS profile of Fluo-PrP[180-195]. 
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Table VI.2.1 Analytical parameters of synthetic PrP peptides.  
 
Peptide Molecular formula 
Exact 
mass 
tR [M+H]+ [M+2H]2+ [M+3H]3+ yield 
PrP[173-195] C112H182N34O36S 2611.32 18.8 n.d. 1306.8 871.5 14% 
PrP[173-195]D178N C112H183N35O35S 2610.33 18.7 n.d. 1306.2 870.9 12% 
PrP[180-195] C77H135N23O25 1782.0 17.7 n.d. 892.0 n.d. 13% 
PrP[180-195]H187A C74H133N21O25 1715.98 18.4 1717.3 858.8 n.d. 10% 
PrP[173-179] C37H52N12O12S 888.35 17.6 888.9 n.d. n.d. 9% 
Fluo-PrP[173-195] C135H198N36O41S2 3043.4 20.6 n.d. 1523.4 1016.3 16% 
Fluo-PrP[180-195] C99H149N25O30S 2200.06 20.3 n.d. 1102.5 734.1 15% 
Fluo-PrP[106-126] C104H155N29O29S3 2370.07 21.7 n.d. 1185.8 790.9 8% 
Fluo-βA[25-35] C69H98N16O19S2 1518.66 22.6 1518.9 760.2 n.d. 12% 
 
 
 
 
Peptide constructs of Table III.5.1 
 
The JMV compounds reported in Table III.5.1 were synthesized by Fmoc standard 
chemistry on D-sized polystyrene Rink-Amide lanterns with a 35 µmol loading as 
schematized in Figure III.5.2.  
Mimotope Synphase Lanterns are well adapted for combinatorial chemistry and 
multiple parallel synthesis. They are constituted of a rigid unreactive polymeric 
support grafted with a mobile phase which can be a polystyrene or polyamide 
copolymer. Lanterns are available with a variety of linkers (the same than 
conventional resin). The reaction was tracked by a visual tagging system using 
colored cogs and spindles.  
The Fmoc deprotection step was carried out by immersing lanterns in piperidine 
(20% v/v in DMF) for 30 min at room temperature. One single flask with a driller 
topped was used. The solution was removed simply reversing the flask.  
Coupling step was performed by immersing the lanterns for 90 min at room 
temperature in a solution containing, per lantern, 420 µL of a 0.4 M Fmoc-AA-OH 
solution in DMF, 420 µL of a 0.8 M DIEA solution in DMF and 420 µL of a 0.4 M 
HBTU solution in DMF. 
Washing step after coupling or deprotection was performed by dipping the lanterns in 
DMF (3 x 3 min) and  DCM (3 x 3 min), successively. The lanterns were allowed to 
air-dry for 15 min after the last DCM washing. 
After the first peptide fragment assembling, different spacers were linked before 
continuing the second peptide fragment assembling. 
On JMV3302, JMV3307, JMV3388, JMV3308 and JMV3389 were coupled different 
anhydrides: glutaric anhydride, succinic anhydride, phthalic anhydride, maleic 
anhydride and glutaric anhydride, respectively.  
The anhydride coupling was performed by immersing each lantern for 2 h at room 
temperature in a solution containing: 420 µL of a 0.4 M anhydride solution in DMF 
and 420 µL of a 0.4 M DIEA solution in DMF. After the anhydride coupling, 
ethylenediamine was linked by dipping the lanterns for 3 h at room temperature in a 
solution containing, per lantern: 350 µL of a 0.1 M N-Fmoc-ethylenediamine solution 
in DMF, 350 µL of a 0.2 M DIEA solution in DMF and 350 µL of a 0.1 M BOP solution 
in DMF. 
On JMV3390 and JMV3391 were coupled N-Fmoc protected 4-
(Aminomethyl)benzoic acid and 4-(Aminophenyl)acetic acid, respectively. This 
coupling was performed by immersing each lantern for 2 h at room temperature in a 
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solution containing: 420 µL of a 0.2 M N-Fmoc protected acid solution in DMF, 420 
µL of a 0.4 M DIEA solution in DMF and 420 µL of a 0.2 M BOP solution in DMF. 
After the second peptide fragment assembling, acetylation was carried out by 
immersing the lanterns in acetic anhydride (50% v/v in DCM). The JMV peptide 
constructs were then cleaved from the lanterns using 2.5 mL per lantern of a solution 
of TFA/TIS/H2O (90:5:5, v/v/v) for 2 h. The TFA solution was reduced under nitrogen 
flow and the cleaved compound was precipitated in cold diethyl ether, washed with 
cold  diethyl ether and then air dried. In Figure VI.2.3 and VI.2.4 are representatively 
reported the LC-MS profiles of JMV3389 and JMV3391. In Table VI.2.2 are listed, 
per peptide: the molecular formula and the exact mass, the retention time (tR) and the 
masses (derived from the LC-MS analyses) and the yield of peptide after purification.   
 
 
 
 
 
 
 
          Figure VI.2.3. LC-MS profile of JMV3389. 
t 
[M+3H]3+ 
[M+2H]2+ 
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          Figure VI.2.4 LC-MS profile of JMV3391. 
 
 
 
 
 
 
           Table VI.2.2 Analytical parameters of JMV synthetic peptide constructs. 
 
Peptide 
constructs 
Molecular 
formula 
Exact 
mass 
tR [M+2H]2+ [M+3H]3+ yield 
JMV3302 C84H137N25O23S 1896.00 1.99 949.58 633.34 10% 
JMV3307 C83H135N25O23S 1881.99 2.02 942.6 628.5 13% 
JMV3388 C87H135N25O23S 1929.99 2.17 966.5 644.6 12% 
JMV3308 C83H133N25O23S 1879.97 2.07 941.46 628.01 9% 
JMV3389 C87H142N26O24S 1967.04 1.96 985.2 657.1 14% 
JMV3390 C91H142N26O24S 2015.04 2.02 1009.1 673.1 11% 
JMV3391 C91H142N26O24S 2015.04 2.04 1009.1 673.0 13% 
 
 
 
 
 
t 
[M+2H]2+ 
[M+3H]3+ 
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VI.3. RP-HPLC Peptide Purification 
 
 
The crude peptides were purified by a Shimadzu LC system equipped with a LC-8A 
pumps model and a SPD-10AV diode array detector, using a Phenomenex Jupiter 
C18 column (250 X 21.2 mm, 15 µm, 300 Å). A flow rate of 20 mL/min and a linear 
gradient from 5% to 70% of B over 30 min were used. Eluent A, water (0.1% TFA); 
eluent B, acetonitrile (0.1% TFA). 
 
 
 
VI.4. LC-MS characterization  
 
 
The identity and purity of peptides reported in Table II.1 were confirmed by LC-MS 
mass analysis using a Finnigan Mass spectrometer system equipped with an 
electrospray ionization source and a Single Quadrupole detector. All analyses were 
carried out using a Phenomenex Jupiter Proteo column (150 X 2.0 mm, 4 µm, 90 Å). 
A flow rate of 0.2 mL/min and a linear gradient from 5% to 70% of B over 20 min 
were used. Eluent A, water (0.05% TFA); eluent B, acetonitrile (0.05 % TFA). 
The identity and purity of JMV compounds reported in Table III.5.1 were confirmed 
by LC-MS mass analysis using a Water Alliance 2690 HPLC coupled to a Micromass 
Platform II spectrometer equipped with an electrospray ionization source and a Triple 
Quadrupole detector. All analyses were carried out using a C18 column (30 X 2.1 
mm, 3.5 µm, 90 Å). A flow rate of 0.6 mL/min and a gradient from 0% to 100% of B 
over 5 min were used. Eluent A, water (0.1% TFA); eluent B, acetonitrile (0.1% TFA). 
 
 
 
VI.5. UV characterization 
 
 
The concentration of peptide solutions used for CD and Fluorescence experiments 
were determined by UV spectroscopy by using a JASCO UV-Vis spectrophotometer 
V550 and a 1.0 cm pathlength quartz cell. The experimental settings were: 40 
nm/min, scanning speed; 0.2 nm, data pitch; medium, response and 1.0 nm, band 
width. 
The concentration of PrP[173-195], PrP[173-195]D178N and PrP[173-179] solutions 
were measured by absorbance at 257.5 nm, assuming a molar extinction coefficient 
of 195 M-1 cm-1 for phenylalanine [169]. The concentration of fluoresceinated peptide 
solutions were measured by absorbance at 482.5 nm, assuming a molar extinction 
coefficient of 92300 M-1 cm-1 for fluorescein [170]. The concentrations of JMV 
compound solutions were measured by absorbance at 275 nm, assuming a molar 
extinction coefficient of 1405 M-1 cm-1 for tyrosine [169]. 
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VI.6. CD characterization 
 
 
All CD spectra were recorded on a Jasco J-810 spectropolarimeter equipped with a 
thermostated water bath using 1.0 or 0.10 cm pathlength quartz cells. Each spectrum 
was obtained averaging three scans and converting the signal to mean residue 
ellipticity in units of deg cm2 dmol-1 res-1. The experimental settings were: 20 nm/min, 
scanning speed; 2.0 nm, band width; 0.2 nm, resolution; 50 mdeg, sensitivity and 4 s, 
response. 
 
 
III.1. Paragraph  
 
Far UV CD spectra of PrP[173-195], PrP[173-195]D178N and PrP[180-195] were 
recorded at room temperature, using 1.0 cm pathlength quartz cell containing 20 µM 
peptide dissolved in 10 mM phosphate buffer at pH 7.0. 
SDS titration experiments were carried out adding to these peptide solutions small 
aliquots from a 12 mM SDS solution in 10 mM phosphate buffer at pH 7.0. 
TFE titration experiments were performed adding to 20 µM peptide solution, at 
neutral pH, pure TFE (up to 50%, v/v). 
 
 
III.2. Paragraph  
 
All working solutions were prepared in Milli-Q water, adjusting the pH value by using 
small amounts of 0.1 M HCl or NaOH. Spectropolarimetric titrations as a function of 
salt concentration were carried out at 20 °C, adding small aliquots from a 200 mM 
salt solution to 3 µM PrP[180-195] and PrP[180-195]H187A aqueous samples in 1.0 
cm pathlength quartz cells. Concentration-dependent experiments were performed at 
20°C by keeping the product of protein concentration and optical pathlength constant, 
which ensured that the number of molecules in the optical path was constant. In 
thermal experiments, PrP[180-195]H187A dissolved in 20 mM Na2SO4 at pH 4.5 was 
heated from 20 to 80°C at the rate of 1°C min−1 and recooled at the same rate. In 
time-dependent experiments, different amounts of PrP[180-195]H187A were 
dissolved in 50 mM Na2SO4 at pH 7.0. 
 
 
III.3. Paragraph  
 
Far UV CD spectra of PrP[173-195] and PrP[173-195]D178N were recorded at room 
temperature, using 1.0 cm pathlength quartz cell containing 20 µM peptide dissolved 
in TFE. Spectra were also collected after addition of increasing amounts of metal 
cations (Zn(II) and Cu(II)) up to a 10:1 metal/peptide molar ratio. 
 
  
III.4. Paragraph  
 
Far UV CD spectra of Fluo-PrP[173-195], Fluo-PrP[180-195], Fluo-PrP[106-126] and 
βA[25-35] were recorded at room temperature, using 1.0 cm pathlength quartz cell 
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containing 10 µM peptide dissolved in Milli-Q water. Spectra were also collected after 
addition of increasing amounts of a 0.5 mM TC  solution up to a 10:1 TC/peptide 
molar ratio. 
 
 
III.5. Paragraph  
 
Far UV CD spectra of JMV compunds were recorded at room temperature, using 0.1 
cm pathlength quartz cell containing 0.1 mM peptide dissolved in Milli-Q water.  
 
 
 
VI.7. NMR experiments 
 
 
All samples were prepared by dissolving each peptide at a final concentration of 2 
mM in TFEd2-OH (99%). NMR spectra were acquired at 300 K on a 600 MHz Bruker 
DRX spectrometer. 1H-13C HSQC [171], 1H TOCSY [172], NOESY [173], double 
quantum filtered COSY [174] and 1H-15N HSQC spectra were used for resonance 
assignments. The H2O solvent resonance was suppressed using the WATERGATE 
pulse sequence [175]. NOESY mixing times were set at 200, 300 and 400 ms to 
follow the NOE build-up rates. 2D-TOCSY experiments were recorded with mixing 
times of 30 and 70 ms. Data were typically apodized with a Gaussian window 
function and zero-filled to 1 K in f1 prior to Fourier transform. NMRPipe [176] and 
NMRView [177] programs were used for data processing and spectral analysis, 
respectively. Spin system identification and assignment of individual resonances 
were carried out by using a combination of TOCSY and DQF-COSY spectra. The 
TOCSY spectra of all peptide solutions showed well resolved resonances for almost 
all residues, and sequence specific assignment was obtained by the combined use of 
TOCSY and NOESY experiments, according to the standard procedure [178]. One-
dimensional NMR spectra were also collected after the addition of small aliquots of a 
0.5 M ZnCl2 aqueous stock solution to the peptide solution. 
 
 
 
VI.8. Structure calculations  
 
 
NOESY spectra at 300 ms mixing time were used for the integration of NOE cross-
peaks. Peak integrals were evaluated by NMRView, transferred to the program 
package DYANA 1.0.6 [179], and converted to upper distance limits by using the 
CALIBA [180] module of DYANA. Distance constraints were then worked out by the 
GRIDSEARCH module to generate a set of allowed dihedral angles. Structure 
calculation was carried out with the macro ANNEAL module by torsion angle 
dynamics. Eighty structures were calculated by TSSA, starting with a total of 10,000 
MD steps and a default value of maximum temperature. The thirty best structures in 
terms of target functions were considered. A total of 193, 150 and 118 distance 
restraints were used for structure calculation of PrP[173-195], PrP[173-195]D178N, 
and PrP[180-195], respectively. These restraints, derived from inter-residue, 
sequential and medium range NOEs, were introduced in SA torsion space calculation 
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performed by DYANA package. The best thirty structures in terms of root mean 
square deviation (RMSD) were selected from 80 structures sampled in TSSA 
calculations. 
 
 
 
VI.9. Neurotoxicity  tests 
 
 
B104 neuroblastoma cells derived from rat central nervous system [144] were grown 
at 37°C, 5% CO2, in Dulbecco’s modified Eagle’s medium, 1 g/L glucose, 
supplemented with 10% fetal bovine serum (FBS), 1.0 mM Na-piruvate, 2.0 mM 
glutamine and antibiotics (penicillin/streptomycin 5000 U/ 5 mg mL) [181]. 
Neuroblastoma cells were plated into 96-well trays and, after a day, peptides were 
added to the culture medium with increasing concentrations from 0 to 55 µM. Cell 
survival was determined after 18, 24, 48 h of incubation. MTT (5mg/mL) was added 
to cell culture for 3 h at 37°C. The MTT formazan product was released from cells by 
addition of dymethilsulfoxide and measured spectrophotometrically at 570 nm [182]. 
Percent of survival was assessed by comparison with untreated cultures (control). 
The FC50 (defined as the 50% fatal concentration) after 48 h exposure were 
estimated by testing peptides over a broad range of concentrations from 0 to 240 µM. 
FC50 values were determined by Hill plot analysis. Results of MTT tests were 
reported as means of three experiments with three replicates for each one and 
analysed by GraphPad Prism 4 software. Comparison of treated cultures versus 
control condition was performed by means of one way-ANOVA (Tukey’s multiple 
comparison). 
 
 
 
VI.10. Fluorescence spectroscopy  
 
 
The fluorimetric titrations relating to the peptides reported in Table II.1(B) were 
carried out at room temperature using a Varian Cary Eclipse fluorescence 
spectrophotometer and 482 nm exciting wavelenght, with 5-nm excitation and 
emission bandwidths. All titrations were carried out at least thrice and the obtained 
values averaged before using them in calculations. Then, modifications of the 
fluorescein emission intensity were recorded at 520 nm and best fitted to a hyperbolic 
curve. 
 
 
III.4. Paragraph  
 
 
TC (10 µM) was added to a fixed volume of 100 nM aqueous solutions of Fluo-
PrP[173-195] or Fluo-PrP[180-195]. TC, in the same conditions, was also added to 
100 nM solutions of the peptides Fluo-βA[25-35] and Fluo-PrP[106-126], used as 
negative control. The fluorescence intensities were used to evaluate the fraction of 
TC bound by α=∆F/∆Fmax, where ∆F is the fluorescence change observed after each 
  
77 
addition and ∆Fmax refers to 100% binding. Then, the apparent dissociation constant 
(KD’) was evaluated by the equation: 
 
α={KD’+P0+T0-[(KD’+P0+T0)2-4P0T0]1/2}/2P0. 
 
Here, P0 and T0 stand for the initial concentration of peptide and the concentration of 
added TC, respectively. This equation describes one-site binding equilibrium 
[183,184] and we assume this hold true for all our systems.  
 
 
III.5. Paragraph  
 
 
JMV compounds (10 µM) were added to a fixed volume of 100 nM aqueous solution 
of Fluo-PrP[173-195]. To evaluate the KD’ of each Fluo-PrP[173-195]/JMV complex 
was followed the same procedure previously described. 
 
 
 
VI.11. Computational analyses  
 
 
TC can exist in different tautomeric forms differing in their protonation state [185]. In 
Figure VI.11.1, a schematic structure of the antibiotic is reported in its neutral form. 
Thus, it is important to verify that our computational results do not depend on the 
selected protonation state of TC. We, therefore, performed all our computational 
analyses (docking calculations and MD simulations) for two different TC tautomers: 
the zwitterionic form (TCzw), which according to the existing experimental indications 
[185] should be predominant at pH ~7, and the ‘neutral’ one (i.e., not exhibiting any 
formal charge separation, TCn), which according to a very recent quantum 
mechanical study has similar stability to TCzw [186]. 
 
 
 
 
 
Figure VI.11.1 The chemical structure of tetracycline in the non-zwitterionic form TCn. Partial MNDO 
atomic charges (in a.u.) are also reported. 
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Docking analysis 
 
The AutoDock 3.0 program package [187] was employed for the generation of 
complexes between the prion fragment and the TC ligand in both its zwitterionic 
(TCzw) and neutral (TCn) forms. TC coordinates were extracted from X-ray structure 
of the complex with the Tet-repressor [188] hydrogens and charges were added 
using InsightII (semi-empirical MNDO calculations were used to compute charges) 
(INSIGHTII, 1998), whereas its active torsions were defined by the Auto- Tors tool of 
the AutoDock package. Affinity grids were generated with 0.55 Å spacing by the 
AutoGrid program for the whole protein target using the Lennard–Jones parameters 
supplied with the program. The Lamarckian genetic algorithm and the pseudo- Solis 
and Wets methods were used for the conformational search. One-hundred runs were 
performed with a maximum number of generations of 10 million per run. The 
parameters used were chosen according to the study by Hetényi and van der Spoel 
[189] proposing a docking procedure without prior knowledge of the binding site. The 
resultant docked conformations of the ligand were clustered and ranked according to 
the default AutoDock scoring function. 
 
 
MD simulations 
 
Both the PrP[173-195] fragment alone and the PrP [173-195] docked to TCzw and to 
TCn tautomers were studied by means of MD simulations. The starting structures of 
MD simulations on the PrP[173-195]/TC complexes were chosen according to Auto- 
Dock results: TCzw is placed like in Rank 3 and TCn like in Rank 1, since they 
represent the most populated clusters of complexes for TCzw and TCn, respectively 
(see Table III.4.1). However, the distances between TC and PrP[173-195] have been 
slightly increased (translation of about 2.5 Å in the direction perpendicular to the helix 
axis) with respect to the AutoDock results to decrease the bias on the MD results due 
to the choice of the starting structure. Coordinates of the prion fragment PrP[173-
195] were extracted from the NMR [14] structure of human PrP[125-228] (PDB entry 
1QLX). TC coordinates were extracted from X-ray structure of the complex [188] 
whereas topological parameters required to undertake the MD study were generated 
by PRODRG program [190] that uses the GROMOS87 force field. Simulations were 
performed at constant temperature within a fixed-volume box filled with SPC [191] 
water molecules by using periodic boundary conditions. The net charges of the three 
systems were compensated by adding 1 Cl¯ ion. Simulations include around 4800 
(box size 50 x 34 x 34) and 5300 (box size 51 x 35 x 32) atoms in the case of the 
fragment alone or the complexes, respectively. The temperature was kept constant at 
300 K using the isothermal Gaussian temperature coupling [192]. LINCS [193] was 
used to constrain bond lengths, allowing a time step of 2 fs. The particle mesh Ewald 
method [194, 195] (grid spacing of 0.12 nm) was used for electrostatic calculations, 
thus properly accounting for long-range interactions. A nonbonded cutoff of 0.9 nm 
for Lennard–Jones potential was used. For all the systems, the solvent was relaxed 
by energy minimization, followed by 15 ps of MD at 300 K, while restraining protein 
atomic positions with a harmonic potential. The systems were then minimized without 
restraints and their temperature brought to 300 K in a stepwise manner: 15-ps-long 
MD runs were carried out at 50, 100, 200, 250, and 300 K before the production runs 
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were started at 300 K. Subsequently all the systems were simulated for 10 ns. For 
each one of the systems, other two independent MD simulations were performed by 
using different random seed generator numbers during the free dynamic. GROMACS 
simulation package [196] was employed to perform the MD simulations, and a 
modification of gromos87 force field [197-199] was used. INSIGHTII (Accelrys) and 
MOLMOL [200] programs were used for model manipulation, visual analysis, and 
figure production. 
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